EP3294297B1 - Pyrimidinonamidverbindungen als pde2-inhibitoren - Google Patents

Pyrimidinonamidverbindungen als pde2-inhibitoren Download PDF

Info

Publication number
EP3294297B1
EP3294297B1 EP16796942.7A EP16796942A EP3294297B1 EP 3294297 B1 EP3294297 B1 EP 3294297B1 EP 16796942 A EP16796942 A EP 16796942A EP 3294297 B1 EP3294297 B1 EP 3294297B1
Authority
EP
European Patent Office
Prior art keywords
oxo
dihydropyrimidine
carboxamide
phenyl
dimethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP16796942.7A
Other languages
English (en)
French (fr)
Other versions
EP3294297A1 (de
EP3294297A4 (de
Inventor
Dong-Ming Shen
Xiaoxia Qian
Bart Harper
Meng Yang
Deping Wang
Yingjian Bo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of EP3294297A1 publication Critical patent/EP3294297A1/de
Publication of EP3294297A4 publication Critical patent/EP3294297A4/de
Application granted granted Critical
Publication of EP3294297B1 publication Critical patent/EP3294297B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the invention relates generally to compounds which act as inhibitors of the phosphodiesterase (PDE) 2 enzyme, compositions and therapeutic uses thereof.
  • PDE phosphodiesterase
  • Schizophrenia is a debilitating disorder affecting the psychic and motor functions of the brain. It is typically diagnosed in individuals in their early to mid-twenties and symptoms include hallucinations and delusions or at the other extreme, anhedonia or social withdrawal. Across the spectrum, the symptoms are indicative of cognitive impairment and functional disabilities. Notwithstanding improvements in antipsychotic treatments, current therapies, including typical (haloperidol) and atypical (clozapine or olanzapine) antipsychotics, have been less than acceptable and result in an extremely high rate of noncompliance or discontinuation of medication. Dissatisfaction with therapy is attributed to lack of efficacy or intolerable and unacceptable side effects. The side effects have been associated with significant metabolic, extrapyramidal, prolactic and cardiac adverse events. See, Lieberman et al., N. Engl. J. Med. (2005) 353:1209-1223 .
  • Cyclic AMP is thought to regulate the activity of cAMP-dependent protein kinase (PKA), which in turn phosphorylates and regulates many types of proteins including ion channels, enzymes and transcription factors.
  • PKA cAMP-dependent protein kinase
  • cGMP is also responsible for downstream regulation of kinases and ion channels.
  • PDEs 3', 5'-cyclic nucleotide specific phosphodiesterases
  • families are further subdivided based on catalytic domain homology and substrate specificity and include the 1) cAMP specific, PDE4A-D, 7A and 7B, and 8A and 8B, 2) cGMP specific, PDE 5A, 6A-C, and 9A, and 3) those that are dual substrate, PDE 1A-C, 2A, 3A and 3B, 10A, and 11A.
  • the homology between the families ranging from 20% to 45%, suggests that it may be possible to develop selective inhibitors for each of these families.
  • PDE2 is highly expressed in the brain, but is also found in many other tissues as well, and therefore has a broad array of function and utility ( J. A. Beavo, et al., Rev. Physio. Biochem. Pharm., 135, 67 (1999 )). Amongst others, PDE2 has been shown to have therapeutic potential in neuronal development, learning, and memory ( W. C. G. van Staveren, et al., Brain Res., 888, 275 (2001 ) and J. O'Donnell, et al., J. Pharm. Exp. Ther., 302, 249 (2002 )); prolactin and aldosterone secretion ( M. O. Velardez, et al., Eur.
  • WO2015060368 discloses pyrimidinone amide compounds with an effect as PDE2 inhibitors.
  • PDE2 e.g., PDE2A
  • Phosphodiesterase 2 Increases Neuronal cGMP, Synaptic Plasticity and Memory Performance, Neuropharmacology, 47(7):1081-92, 2004 ).
  • PDE2A inhibition was also shown to improve cognitive deficits that develop in aging and Alzheimer's disease ( Domek-Lopacinska and Strosznajder, The Effect of Selective Inhibition of Cyclic GMP Hydrolyzing Phosphodiesterases 2 and 5 on Learning and Memory Processes and Nitric Oxide Synthetase Activity in Brain During Aging, Brain Research, 1216:68-77, 2008 ).
  • the role of PDE2 inhibition in cognitive disorders was also shown in Brandon et al., Potential CNS Applications for Phosphodiesterase Enzyme Inhibitors, Annual Reports in Medicinal Chemistry 42: 4-5, 2007 (compound BAY 60-7550 was reported to have significant potency at other PDE isoforms, had high clearance and limited brain penetration). See also Jorgenson, et al, Annual Reports in Medicinal Chemistry 48: 37-55, 2013. "Selective Inhibitors of PDE2, PDE9, and PDE10: Modulators of Activity of the Central Nervous System ".
  • PDE2 inhibitors have also been shown to have efficacy in preclinical models of anxiety and depression ( Masood et al., Anxiolytic Effects of Phosphodiesterase-2 Inhibitors Associated with Increased cGMP Signaling, JPET 331(2):690-699, 2009 ; Masood et al., Reversal of Oxidative Stress-Induced Anxiety by Inhibition of Phosphodiesterase-2 in Mice, JPET 326(2):369-379, 2008 ; Reierson et al., Repeated Antidepressant Therapy Increases Cyclic GMP Signaling in Rat Hippocampus, Neurosci. Lett., 466(3):149-53, 2009 ).
  • PDE2 and PDE3 in the endothelium can act as a sensor or switch to detect normal versus pathological concentrations of cGMP and thus regulate endothelial permeability accordingly with potential relevance to migraine.
  • PDE2 and PDE3 in the endothelium can act as a sensor or switch to detect normal versus pathological concentrations of cGMP and thus regulate endothelial permeability accordingly with potential relevance to migraine.
  • Cerebral vasodilation is considered a major cause of migraine. See P. C. Tfelt-Hansen and P. J. Koehler, One hundred years of migraine research: major clinical and scientific observations from 1910 to 2010, Headache, 2011. 51(5), 752-578 and D. K. Arulmozhi et al., Migraine: current therapeutic targets and future avenues, Current Vascular Pharmacology, 2006, 4(2), 117-128 . Therefore, PDE2 inhibition may have utility as a treatment or prophylactic for migraine.
  • PDE2 modulators believed to be useful for treating diseases or disorders associated with PDE2 such as Alzheimer's disease, cognitive impairment associated with schizophrenia, depression, migraines, and the like continues to exist.
  • Inhibitors of PDE2 are not only believed to be useful in treating schizophrenia but also a wide variety of conditions or disorders that would benefit from increasing levels of cAMP and/or cGMP within neurons, including a variety of neurological, psychotic, anxiety and/or movement disorders. Accordingly, agents that inhibit PDE2 and PDE2A would be desirable as therapeutics for neurological and psychiatric disorders.
  • the present invention is directed to pyrimidinone amide compounds which may be useful as therapeutic agents for the treatment of central nervous system and/or peripheral disorders associated with phosphodiesterase 2 (PDE2).
  • PDE2 phosphodiesterase 2
  • the present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Alzheimer's, cognitive impairment, anxiety, depression, migraines, or Huntington's disease, Parkinson's disease, Parkinson's disease dementia (PDD), and other diseases associated with striatal hypofunction or basal ganglia dysfunction.
  • neurological and psychiatric disorders such as schizophrenia, psychosis, Alzheimer's, cognitive impairment, anxiety, depression, migraines, or Huntington's disease, Parkinson's disease, Parkinson's disease dementia (PDD), and other diseases associated with striatal hypofunction or basal ganglia dysfunction.
  • the present invention is directed to pyrimidinone amide compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein:
  • R 1a is C 1-6 alkyl.
  • heterocyclyl of R 1 is selected from the group consisting of optionally substituted oxetanyl, tetrahydrofuranyl, piperidinyl, pyrrolidinyl, morpholinyl, dihydropyrrolopyrazolyl, dihydropyrrolopyrimindyl, tetrahydropyranyl, pyrazolyl, and azetidinyl.
  • Another embodiment of the invention of the formula I is realized when the aryl of R 1 is phenyl.
  • Still another embodiment of the invention of formula I is realized when the cycloalkyl of R 1 is selected from the group consisting of optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • R 1 is selected from the group consisting of OR, O(CH 2 ) 1-3 OR, O(CH 2 ) n C(R) 2 OR, and O(CH 2 ) 1-3 N(R) 2 .
  • R 1 is selected from the group O-(CH 2 ) n C 4-10 heterocyclyl said heterocyclyl optionally substituted with one to three groups of R a .
  • R 1 is selected from the group O-(CH 2 ) 1-3 OC 6-10 aryl and O-C 6-10 aryl, said aryl optionally substituted with one to three groups of R a .
  • R 1 is selected from the group N(R X ) 2 , -NRC 5-10 heterocyclyl, -NRC 6-10 aryl,-and NRC 3-10 cycloalkyl, said cycloalkyl, aryl and heterocyclyl optionally substituted with one to three groups of R a .
  • R 1 is N(R X ) 2 .
  • Still another subembodiment of this aspect of the invention is realized when two adjacent R X groups combine together with the nitrogen atom to which they are attached to form a C 4-10 heterocyclyl and optionally substituted with one to three groups of R b .
  • Yet another subembodiment of this aspect of the invention is realized when two adjacent R X groups combine together with the nitrogen atom to which they are attached to form a C 4-10 heterocyclyl selected from the group consisting of optionally substituted pyrrolidinyl, pyrazolyl, azetidinyl, piperidinyl, morpholinyl, dihydropyrrolopyrazolyl, dihydropyrrolopyrimidinyl, and dihydropyrrolopyridinyl.
  • Still another embodiment of the invention of formulas I is realized when R 1 is SR.
  • R 1 is selected from the group consisting of SCH 3 , -N(CH 3 ) 2 , N(CH 3 )(CH 2 CH 3 ), N(CH 2 CH 3 ) 2 , -NH 2 , -NHCH 3 , NH-cyclobutyl, NH-cyclopentyl, NH-cyclopropyl, NH-pyridyl, -OR, -O-phenyl, -O(CH 2 ) 2 OCH 3 , -O(CH 2 ) 3 OCH 3 , -O(CH 2 ) 3 OCH(CH 3 ) 2 , -O(CH 2 ) 2 N(CH 3 ) 2 , -O(CH 2 ) 2 C(CH3) 2 OCH 3 , -OCH 2 oxetanyl, -O(CH 2 ) 4 OCH 3 , -O(CH 2 ) 3 NHCH 3 , -O-tetra
  • Another subembodiment of the invention of formula I is realized when R 1 is -N(CH 3 ) 2 .
  • Another subembodiment of the invention of formula I is realized when R 1 is -NH 2 .
  • Another subembodiment of the invention of formula I is realized when R 1 is -NH(CH 3 ). Another subembodiment of the invention of formula I is realized when R 1 is O(CH 2 ) 3 NHCH 3 . Another subembodiment of the invention of formula I is realized when R 1 is optionally substituted N-linked pyrazolyl. Another subembodiment of the invention of formula I is realized when R 1 is optionally substituted N-linked piperidinyl, or O-piperidinyl (e.g., 3- or 4- O-piperidinyl). Another subembodiment of the invention of formula I is realized when R 1 is optionally substituted N-linked pyrrolidinyl, or O-(3-pyrrolidinyl).
  • R 2 and R 3 are C 1-6 alkyl, said alkyl optionally substituted with one to three groups of R b .
  • R 2 and R 3 is hydrogen or CH 3 and the other is C 1-6 alkyl or C 3-10 cycloalkyl, said alkyl and cycloalkyl optionally substituted with one to three groups of R b .
  • a subembodiment of this aspect of the invention is realized when the alkyl is selected from the group consisting of CH 3 , CH(CH 3 ) 2 , CH 2 CH 3 , C(CH 3 ) 3 .
  • Another subembodiment of this aspect of the invention is realized when the alkyl is CH 3 .
  • Another subembodiment of this aspect of the invention is realized when the alkyl is CH(CH 3 ) 2 .
  • Another subembodiment of this aspect of the invention is realized when the alkyl is C(CH 3 ) 3. Another subembodiment of this aspect of the invention is realized when the alkyl is CH 2 CH 3 .
  • An aspect of this embodiment of the invention of formula I is realized when one of R 2 and R 3 is hydrogen and the other is CH 3 .
  • An aspect of this embodiment of the invention of formula I is realized when one of R 2 and R 3 is hydrogen and the other is CH 2 CH 3
  • An aspect of this embodiment of the invention of formula I is realized when one of R 2 and R 3 is hydrogen and the other is C(CH 3 ) 3
  • Still another aspect of this embodiment of the invention of formula I is realized when one of R 2 and R 3 is hydrogen and the other is CH(CH 3 ) 2 .
  • Another embodiment of the invention of formula I is realized when one of R 2 and R 3 is hydrogen and the other is optionally substituted C 3-10 cycloalkyl.
  • An aspect of this embodiment of the invention is realized when the cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, and cyclopentyl.
  • a subembodiment of this aspect of the invention is realized when the cycloalkyl is cyclopropyl.
  • Another subembodiment of this aspect of the invention is realized when the cycloalkyl is cyclobutyl.
  • Another subembodiment of this aspect of the invention is realized when the cycloalkyl is cyclopentyl.
  • Another embodiment of the invention of formula I is realized when one of R 2 and R 3 is hydrogen and the other is optionally substituted C 6-10 aryl, said aryl optionally substituted with one to three groups of R b .
  • Another embodiment of the invention of formula I is realized when one of R 2 and R 3 is hydrogen and the other is optionally substituted C 5-10 heteroaryl, said heteroaryl optionally substituted with one to three groups of R b .
  • R 2 and R 3 are hydrogen and the other is selected from (CH 2 ) n CN, C(O)R, C(O)OR, and CF 3 .
  • Still another embodiment of the invention of formula I is realized when R 2 and R 3 combine with the carbon atom to which they are attached to form a C 3-10 cycloalkyl, said cycloalkyl optionally substituted with one to three groups of R b .
  • An aspect of this embodiment of the invention is realized when the optionally substituted cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, and cyclopentyl.
  • a subembodiment of this aspect of the invention is realized when the cycloalkyl is cyclopropyl.
  • Another subembodiment of this aspect of the invention is realized when the cycloalkyl is cyclobutyl.
  • Another subembodiment of this aspect of the invention is realized when the cycloalkyl is cyclopentyl.
  • An embodiment of the invention of formula I is realized when R 2 and R 3 along with the carbon atom to which they are attached and the R 4 on the phenyl ring combine to form a C6-10 bicyclic ring which includes the phenyl ring, said bicyclic ring optionally interrupted with 1-2 heteroatoms selected from O, S, and N and optionally substituted.
  • R a is selected from OH, halo, CH 3 , optionally substituted cyclopropyl, (CH 2 ) n OCH 3 , CF 2 R, CH 2 F, (CH 2 ) n CF 3 , OCHF 2 , OCF 3 , SCH 3 , SCF 3 , SF 5 , SOCF 3 , SO 2 CF 3 , SO 2 CH 3 , CH 2 NH 2 , and (CH 2 ) n N(CH 3 ) 2 .
  • R a is selected from (CH 2 ) n OCH 3 , CH 2 F, (CH 2 ) n CF 3 , OCHF 2 , OCF 3 , SCH 3 , SCF 3 , and SF 5 .
  • Another embodiment of the invention of formula I is realized when n is 0. Another embodiment of the invention of formula I is realized when n is 1. Another embodiment of the invention of formula I is realized when n is 2. Another embodiment of the invention of formula I and II is realized when n is 3. Still another embodiment of the invention of formula I is realized when n of R a is 0-1, 0-2, or 0-3.
  • Still another embodiment of the invention of formula I is represented by structural formula II: or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from the group consisting of - N(CH 3 ) 2 , NH 2 , NHCH 3 , O(CH 2 ) 3 NHCH 3 , and optionally substituted O-tetrahydrofuranyl, N linked pyrazolyl, N linked pyrrolidinyl, O-(3-pyrrolidinyl), O-(3-piperidinyl), or O-(4-piperidinyl), R 3 is selected from the group consisting of CH 3 , CH(CH 3 ) 2 , CH 2 CH 3 , C(CH 3 ) 3 and optionally substituted cyclopropyl, and R a is selected from the group consisting of SCF 3 , CF 3 , OCHF 2 , OCF 3 , and CH 2 CF 3 .
  • R 1 is selected from the group consisting of -N(CH 3 ) 2 , NH 2 , NHCH 3 , and optionally substituted 1-pyrrolidinyl
  • R 3 is selected from the group consisting of CH 3 , CH(CH 3 ) 2 , CH 2 CH 3 , C(CH 3 ) 3 and optionally substituted cyclopropyl
  • R a is CF 3 .
  • the invention is also directed to a method for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2) using the compounds of Formula I and II. More specifically, the present invention relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Alzheimer's, cognitive impairment, anxiety, depression, migraines, or Huntington's disease, Parkinson's disease, Parkinson's disease dementia, and other diseases associated with striatal hypofunction or basal ganglia dysfunction using the compounds of formula I and II.
  • neurological and psychiatric disorders such as schizophrenia, psychosis, Alzheimer's, cognitive impairment, anxiety, depression, migraines, or Huntington's disease, Parkinson's disease, Parkinson's disease dementia, and other diseases associated with striatal hypofunction or basal ganglia dysfunction using the compounds of formula I and II.
  • the invention also encompasses pharmaceutical compositions containing a compound of formula I and II and methods for treatment or prevention of phosphodiesterase mediated diseases using compounds of formula I and II.
  • variable occurs more than once in any formula of the invention, or in a substituent thereof, the individual occurrences of that variable are independent of each other, unless otherwise specified. Also, combinations of substituents/or variables are permissible only if such combinations result in stable compounds and valency is permissible.
  • alkyl by itself or as part of another substituent, means a saturated straight or branched chain hydrocarbon radical having the number of carbon atoms designated (e.g., C 1-10 alkyl means an alkyl group having from one to ten carbon atoms).
  • Preferred alkyl groups for use in the invention are C 1-6 alkyl groups, having from one to six atoms.
  • Exemplary alkyl groups include methyl, ethyl, n -propyl, isopropyl, n -butyl, isobutyl, tert -butyl, pentyl, hexyl, and the like.
  • C 0 alkyl means a bond.
  • cycloalkyl by itself or as part of another substituent, means a saturated cyclic hydrocarbon radical having the number of carbon atoms designated (e.g. , C 3-12 cycloalkyl means a cycloalkyl group having from three to twelve carbon atoms).
  • cycloalkyl as used herein includes mono-, bi- and tricyclic saturated carbocycles, spirocycles, and bridged and fused ring carbocycles.
  • Preferred cycloalkyl groups for use in the invention are monocyclic C 3-8 cycloalkyl groups, having from three to eight carbon atoms.
  • Exemplary monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
  • Exemplary bridged cycloalkyl groups include adamantyl and norbornyl.
  • Exemplary fused cycloalkyl groups include decahydronaphthalene.
  • aryl by itself or as part of another substituent, means an aromatic cyclic hydrocarbon radical. Preferred aryl groups have from six to ten carbons atoms. The term “aryl” includes multiple ring systems as well as single ring systems. Preferred aryl groups for use in the invention include phenyl and naphthyl.
  • aryl also includes fused cyclic hydrocarbon rings which are partially aromatic (i.e., one of the fused rings is aromatic and the other is non-aromatic).
  • An exemplary aryl group which is partially aromatic is indanyl.
  • heterocyclyl, heterocycle or heterocyclic represents a stable 5- to 7-membered monocyclic or stable 8- to 11-membered bicyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
  • heterocyclyl, heterocycle or heterocyclic includes heteroaryl moieties.
  • heterocyclic elements include, but are not limited to, azepinyl, benzodioxolyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzotriazolyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, 1,3-dioxolanyl, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazoly
  • heteroaryl represents a stable 5- to 7-membered monocyclic- or stable 9- to 10-membered fused bicyclic heterocyclic ring system which contains an aromatic ring, any ring of which may be saturated, such as piperidinyl, partially saturated, or unsaturated, such as pyridinyl, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
  • the substituent When a heterocyclyl group as defined herein is substituted, the substituent may be bonded to a ring carbon atom of the heteroaryl group, or on a ring heteroatom (i.e., a nitrogen, oxygen or sulfur), which has a valence which permits substitution. Preferably, the substituent is bonded to a ring carbon atom.
  • the point of attachment may be at a ring carbon atom of the heteroaryl group, or on a ring heteroatom (i.e., a nitrogen, oxygen or sulfur), which has a valence which permits attachment.
  • the attachment is at a ring carbon atom.
  • halo or “halogen” includes fluoro, chloro, bromo and iodo.
  • haloalkyl means an alkyl, as defined above, wherein one or more of the bonding positions on the alkyl moiety typically occupied by hydrogen atoms are instead occupied by a halo group
  • perhaloalkyl or “fully halogenated” alkyl means that all bonding positions not participating in bonding the alkyl substituent to a substrate are occupied by a halogen, for example, where the alkyl is selected to be methyl, the term perfluoroalkyl means -CF 3 .
  • One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both both solvated and unsolvated forms.
  • “Solvate” means a physical association of a compound of the invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate”encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates and the like.
  • “Hydrate” is a solvate wherein the solvent molecule is H 2 0.
  • the compounds of the invention may have one or more asymmetric centers.
  • Compounds with asymmetric centers give rise to enantiomers (optical isomers), diastereomers (configurational isomers) or both, and it is intended that all of the possible enantiomers and diastereomers in mixtures and as pure or partially purified compounds are included within the scope of this invention.
  • the present invention is meant to encompass all such isomeric forms of the compounds of the invention.
  • the present invention includes all stereoisomers of formulae (I) and pharmaceutically acceptable salts thereof.
  • racemic mixtures of the compounds may be separated so that the individual enantiomers or diastereomers are isolated.
  • the separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography.
  • the coupling reaction is often the formation of salts using an enantiomerically pure acid or base.
  • the diastereomeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue.
  • the racemic mixture of the compounds can also be separated directly by chromatographic methods using chiral stationary phases, which methods are well known in the art.
  • any enantiomer or diastereomer of a compound may be obtained by stereoselective synthesis using optically pure starting materials or reagents of known configuration by methods well known in the art.
  • the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature.
  • the present invention is meant to include all suitable isotopic variations of the compounds of generic formulas I and Ia.
  • Protium is the predominant hydrogen isotope found in nature.
  • Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. While 12 C and 19 F are the predominant isotopes of carbon and fluorine found in nature, enriching for 11 C or 18 F may afford advantages, particularly for use in imaging via positron emission tomography (PET).
  • PET positron emission tomography
  • a preferred substance for potential use as a PET imaging agent would effectively inhibit the PDE2 enzyme with a Ki value less than or about 0.5 nM, where compounds tested are comprised of naturally occurring isotopes. Such preferred substances, when enriched with 11 C or 18 F, may be therefore be useful as PET imaging agents.
  • Isotopically enriched compounds within generic formula I and II can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically enriched reagents and/or intermediates.
  • substantially pure means that the isolated material is at least 90% pure, and preferably 95% pure, and even more preferably 99% pure as assayed by analytical techniques known in the art.
  • the compounds of the present invention may contain one or more stereogenic centers and can thus occur as racemates, racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within the ambit of this invention. Any formulas, structures or names of compounds described in this specification that do not specify a particular stereochemistry are meant to encompass any and all existing isomers as described above and mixtures thereof in any proportion. When stereochemistry is specified, the invention is meant to encompass that particular isomer in pure form or as part of a mixture with other isomers in any proportion.
  • references to the compounds of present invention are meant to also include the pharmaceutically acceptable salts, and also salts that are not pharmaceutically acceptable when they are used as precursors to the free compounds or in other synthetic manipulations.
  • the compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases.
  • Salts derived from such inorganic bases include aluminum, ammonium, calcium, cupric, cuprous, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the like salts. Particular embodiments include the ammonium, calcium, magnesium, potassium, and sodium salts. Salts in the solid form may exist in more than one crystal structure, and may also be in the form of hydrates.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N '-dibenzylethylene-diamine, diethylamine, 2-diethylaminoethanol, 2-dimethylamino-ethanol, ethanolamine, ethylenediamine, N -ethyl-morpholine, N -ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
  • salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like.
  • the subject compounds may be useful in a method of treating a neurological or psychiatric disorder associated with PDE2 dysfunction in a patient such as a mammal in need of such inhibition comprising the administration of an effective amount of the compound.
  • a neurological or psychiatric disorder associated with PDE2 dysfunction in a patient such as a mammal in need of such inhibition comprising the administration of an effective amount of the compound.
  • a variety of other mammals can be treated according to the method of the present invention.
  • the subject compounds may be useful in a method of inhibiting PDE2 activity in a patient such as a mammal in need of such inhibition comprising the administration of an effective amount of the compound.
  • the subject compounds also may be useful for treating a neurological or psychiatric disorder associated with striatal hypofunction or basal ganglia dysfunction in a mammalian patient in need thereof.
  • a neurological or psychiatric disorder associated with striatal hypofunction or basal ganglia dysfunction in a mammalian patient in need thereof.
  • primates, especially humans a variety of other mammals can be treated according to the method of the present invention.
  • the present invention is directed to a compound of the present invention or a pharmaceutically acceptable salt thereof for use in medicine.
  • the present invention is further directed to a use of a compound of the present invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a neurological or psychiatric disorder associated with PDE2 function in a mammalian patient in need thereof.
  • the present invention is further directed to a use of a compound of the present invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a neurological or psychiatric disorder associated with striatal hypofunction or basal ganglia dysfunction in a mammalian patient in need thereof.
  • Treating" or “treatment of' a disease state includes: 1) inhibiting the disease state, i.e., arresting the development of the disease state or its clinical symptoms; 2) or relieving the disease state, i.e., causing temporary or permanent regression of the disease state or its clinical symptoms. "Treating” or “treatment of' does not include curing or preventing the disease from occurring.
  • the subject treated in the present methods is generally a mammal, in particular, a human being, male or female, in whom therapy is desired.
  • the term "therapeutically effective amount” means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician. It is recognized that one skilled in the art may affect the neurological and psychiatric disorders by treating a patient presently afflicted with the disorders or by prophylactically treating a patient afflicted with such disorders with an effective amount of the compound of the present invention.
  • inhibitors of PDE2, including PDE2A will provide therapeutic benefit to those individuals suffering from psychiatric and cognitive disorders.
  • inhibition of PDE2A in the striatum will result in increased cAMP/cGMP signaling and striatal output, which has the potential to restore behavioral inhibition that is impaired in cognitive disease such as schizophrenia.
  • compounds of the invention provide a method for treating or ameliorating diseases or conditions in which striatal hypofunction is a prominent feature or ones in which basal ganglia dysfunction plays a role, such as, Parkinson's disease, Parkinson's disease dementia (PDD), Huntington's disease, schizophrenia, obsessive-compulsive disorders, addiction and psychosis.
  • diseases or conditions in which striatal hypofunction is a prominent feature or ones in which basal ganglia dysfunction plays a role such as, Parkinson's disease, Parkinson's disease dementia (PDD), Huntington's disease, schizophrenia, obsessive-compulsive disorders, addiction and psychosis.
  • Other conditions for which the inhibitors described herein may have a desirable and useful effect include those requiring a reduction in activity and reduced response to psychomotor stimulants or where it would be desirable to reduce conditional avoidance responses, which is often predictive of clinical antipsychotic activity.
  • the compounds of this invention there is provided a method for treating or ameliorating diseases or conditions in neuronal development, learning, and memory, prolactin and aldosterone secretion, bone cell differentiation, growth, and bone resorption, immunological response, vascular angiogenesis, inflammatory cell transit, cardiac contraction, platelet aggregation, female sexual arousal disorder, and hypoxic pulmonary vasoconstriction.
  • selective PDE2 inhibitor refers to an organic molecule that effectively inhibits an enzyme from the PDE2 family to a greater extent than enzymes from the PDE 1, and 3-11 families.
  • a selective PDE2 inhibitor is an organic molecule having a Ki for inhibition of PDE2 that is less than or about one-tenth that for a substance that is an inhibitor for another PDE enzyme.
  • the organic molecule inhibits PDE2 activity to the same degree at a concentration of about one-tenth or less than the concentration required for any other PDE enzyme.
  • a selective PDE2 inhibitor is an organic molecule, having a Ki for inhibition of PDE2 that is less than or about one-hundredth that for a substance that is an inhibitor for another PDE enzyme.
  • the organic molecule inhibits PDE2 activity to the same degree at a concentration of about one-hundredth or less than the concentration required for any other PDE enzyme.
  • a selective PDE2 inhibitor is an organic molecule, having a Ki for inhibition of PDE2 that is less than or about five-hundredth that for a substance that is an inhibitor for another PDE enzyme.
  • the organic molecule inhibits PDE2 activity to the same degree at a concentration of about five-hundredth or less than the concentration required for any other PDE enzyme.
  • a "selective PDE2 inhibitor” can be identified, for example, by comparing the ability of an organic molecule to inhibit PDE2 activity to its ability to inhibit PDE enzymes from the other PDE families.
  • an organic molecule may be assayed for its ability to inhibit PDE2 activity, as well as PDE1A, PDE1B, PDE1C, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A, PDE6A, PDE6B, PDE6C, PDE7A, PDE7B, PDE8A, PDE8B, PDE9A, PDE10 and/or PDE11A.
  • Phosphodiesterase enzymes including PDE2 have been implicated in a wide range of biological functions. This has suggested a potential role for these enzymes in a variety of disease processes in humans or other species.
  • the compounds of the present invention may have utility in treating a variety of neurological and psychiatric disorders.
  • compounds of the present invention are provided for use in treating schizophrenia or psychosis comprising administering to a patient in need thereof an effective amount of a compound of the present invention.
  • the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) (2000, American Psychiatric Association, Washington DC ) provides a diagnostic tool that includes paranoid, disorganized, catatonic or undifferentiated schizophrenia and substance-induced psychotic disorders.
  • DSM-IV-TR The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) (2000, American Psychiatric Association, Washington DC ) provides a diagnostic tool that includes paranoid, disorganized, catatonic or undifferentiated schizophrenia and substance-induced psychotic disorders.
  • the term "schizophrenia or psychosis” includes the diagnosis and classification of these mental disorders as described in DSM-IV-TR and the term is intended to include similar disorders described in other sources.
  • Disorders and conditions encompassed herein include, but are not limited to, conditions or diseases such as schizophrenia or psychosis, including schizophrenia (paranoid, disorganized, catatonic, undifferentiated, or residual type), schizophreniform disorder, schizoaffective disorder, for example of the delusional type or the depressive type, delusional disorder, psychotic disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition and substance-induced or drug-induced (for example psychosis induced by alcohol, amphetamine, cannabis, ***e, hallucinogens, inhalants, opioids, phencyclidine, ketamine and other dissociative anaesthetics, and other psychostimulants), psychosispsychotic disorder, psychosis associated with affective disorders, brief reactive psychosis, schizoaffective psychosis, "schizophrenia-spectrum" disorders such as schizoid or schizotypal personality disorders, personality disorder of the paranoid type, personality disorder of the schizo
  • the compounds of the present invention are provided for use in treating cognitive disorders comprising administering to a patient in need thereof an effective amount of a compound of the present invention.
  • the DSM-IV-TR also provides a diagnostic tool that includes cognitive disorders including dementia, delirium, amnestic disorders and age-related cognitive decline.
  • cognitive disorders includes the diagnosis and classification of these disorders as described in DSM-IV-TR and the term is intended to include similar disorders described in other sources.
  • disorders and conditions encompassed herein include, but are not limited to, disorders that comprise as a symptom a deficiency in attention and/or cognition, such as dementia (associated with Alzheimer's disease, ischemia, multi-infarct dementia, trauma, intracranial tumors, cerebral trauma, vascular problems or stroke, alcoholic dementia or other drug-related dementia, AIDS, HIV disease, Parkinson's disease, Parkinson's disease dementia (PDD), Huntington's disease, Pick's disease, Creutzfeldt Jacob disease, perinatal hypoxia, other general medical conditions or substance abuse), Alzheimer's disease, multi-infarct dementia, AIDS-related dementia, and Fronto temperal dementia, delirium, amnestic disorders or age related cognitive decline.
  • dementia associated with Alzheimer's disease, ischemia, multi-infarct dementia, trauma, intracranial tumors, cerebral trauma, vascular problems or stroke
  • alcoholic dementia or other drug-related dementia AIDS
  • HIV disease Parkinson's disease
  • Parkinson's disease dementia Parkinson's disease dementia (PDD
  • compounds of the present invention are provided for use in treating anxiety disorders comprising administering to a patient in need thereof an effective amount of a compound of the present invention.
  • the DSM-IV-TR also provides a diagnostic tool that includes anxiety disorders as generalized anxiety disorder, obsessive-compulsive disorder and panic attack.
  • anxiety disorders includes the diagnosis and classification of these mental disorders as described in DSM-IV-TR and the term is intended to include similar disorders described in other sources.
  • Disorders and conditions encompassed herein include, but are not limited to, anxiety disorders such as, acute stress disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic attack, panic disorder, post-traumatic stress disorder, separation anxiety disorder, social phobia, specific phobia, substance-induced anxiety disorder and anxiety due to a general medical condition.
  • anxiety disorders such as, acute stress disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic attack, panic disorder, post-traumatic stress disorder, separation anxiety disorder, social phobia, specific phobia, substance-induced anxiety disorder and anxiety due to a general medical condition.
  • compounds of the present invention are described for use in treating substance-related disorders and addictive behaviors comprising administering to a patient in need thereof an effective amount of a compound of the present invention.
  • the DSM-IV-TR also provides a diagnostic tool that includes persisting dementia, persisting amnestic disorder, psychotic disorder or anxiety disorder induced by substance abuse, and tolerance of, dependence on or withdrawal from substances of abuse.
  • the term "substance-related disorders and addictive behaviors” includes the diagnosis and classification of these mental disorders as described in DSM-IV-TR and the term is intended to include similar disorders described in other sources.
  • Disorders and conditions encompassed herein include, but are not limited to, substance-related disorders and addictive behaviors, such as substance-induced delirium, persisting dementia, persisting amnestic disorder, psychotic disorder or anxiety disorder, drug addiction, tolerance, and dependence or withdrawal from substances including alcohol, amphetamines, cannabis, ***e, hallucinogens, inhalants, nicotine, opioids, phencyclidine, sedatives, hypnotics or anxiolytics.
  • substance-related disorders and addictive behaviors such as substance-induced delirium, persisting dementia, persisting amnestic disorder, psychotic disorder or anxiety disorder, drug addiction, tolerance, and dependence or withdrawal from substances including alcohol, amphetamines, cannabis, ***e, hallucinogens, inhalants, nicotine, opioids, phencyclidine, sedatives, hypnotics or anxiolytics.
  • compounds of the present invention are described for use in treating obesity or eating disorders associated with excessive food intake, and complications associated therewith, comprising administering to a patient in need thereof an effective amount of a compound of the present invention.
  • obesity is included in the tenth edition of the International Classification of Diseases and Related Health Problems (ICD-10) (1992 World Health Organization) as a general medical condition.
  • the DSM-IV-TR also provides a diagnostic tool that includes obesity in the presence of psychological factors affecting medical condition.
  • the term "obesity or eating disorders associated with excessive food intake” includes the diagnosis and classification of these medical conditions and disorders described in ICD-2 and DSM-IV-TR and the term is intended to include similar disorders described in other sources.
  • Disorders and conditions encompassed herein include, but are not limited to, obesity, bulimia nervosa and compulsive eating disorders.
  • compounds of the present invention are described for use in treating mood and depressive disorders comprising administering to a patient in need thereof an effective amount of a compound of the present invention.
  • the term "mood and depressive disorders” includes the diagnosis and classification of these medical conditions and disorders described in the DSM-IV-TR and the term is intended to include similar disorders described in other sources.
  • disorders and conditions encompassed herein include, but are not limited to, bipolar disorders, mood disorders including depressive disorders, major depressive episode of the mild, moderate or severe type, a manic or mixed mood episode, a hypomanic mood episode, a depressive episode with atypical features, a depressive episode with melancholic features, a depressive episode with catatonic features, a mood episode with postpartum onset, post-stroke depression; major depressive disorder, dysthymic disorder, minor depressive disorder, premenstrual dysphoric disorder, post-psychotic depressive disorder of schizophrenia, a major depressive disorder superimposed on a psychotic disorder such as delusional disorder or schizophrenia, a bipolar disorder, for example, bipolar I disorder, bipolar II disorder, cyclothymic disorder, depression including unipolar depression, seasonal depression and post-partum depression, premenstrual syndrome (PMS) and premenstrual dysphoric disorder, mood disorders due to a general medical condition, and substance-induced mood disorders.
  • a bipolar disorder for example,
  • compounds of the present invention are described for use in treating pain comprising administering to a patient in need thereof an effective amount of a compound of the present invention.
  • Particular pain embodiments are bone and joint pain (osteoarthritis), repetitive motion pain, dental pain, cancer pain, myofascial pain (muscular injury, fibromyalgia), perioperative pain (general surgery, gynecological), chronic pain and neuropathic pain.
  • compounds of the invention are described for use in treating other types of cognitive, learning and mental related disorders including, but not limited to, learning disorders, such as a reading disorder, a mathematics disorder, or a disorder of written expression, attention-deficit/hyperactivity disorder, age-related cognitive decline, pervasive developmental disorder including autistic disorder, attention disorders such as attention-deficit hyperactivity disorder (ADHD) and conduct disorder; an NMDA receptor-related disorder, such as autism, depression, benign forgetfulness, childhood learning disorders and closed head injury; a neurodegenerative disorder or condition, such as neurodegeneration associated with cerebral trauma, stroke, cerebral infarct, epileptic seizure, neurotoxin poisoning, or hypoglycemia-induced neurodegeneration; multi-system atrophy; movement disorders, such as akinesias and akinetic-rigid syndromes (including, Parkinson's disease, Parkinson's disease dementia (PDD), drug-induced parkinsonism, post-encephalitic parkinsonism, progressive supranuclear pals
  • learning disorders such
  • PMS premenstrual syndrome
  • premenstrual dysphoric disorder learning disorders, pervasive developmental disorders, including autistic disorder, attention disorders including Attention-Deficit/Hyperactivity Disorder, autism, tic disorders including Tourette's disorder, anxiety disorders including phobia and post-traumatic stress disorder, cognitive disorders associated with dementia, AIDS dementia, Alzheimer's, Parkinson's disease, Parkinson'
  • Angiogenesis is the physiological process through which new blood vessels form, and agents that inhibit this process have been shown to be effective treatments for some cancers.
  • PDE2 inhibition may have utility as a treatment for cancer. See Savai, et al, Targeting cancer with phosphodiesterase inhibitors, Expert Opin. Investig. Drugs (2010) 19(1):117-131 .
  • PDE2 has been shown to be expressed in human vascular endothelial cells (VECs) and inhibition of PDE2 by treatment with selective inhibitors inhibited VEGF promoted migration of VECs.
  • the subject compounds may be further useful for use in the prevention, treatment, control, amelioration, or reduction of risk of the diseases, disorders and conditions noted herein.
  • the subject compounds are further useful in a method for the prevention, treatment, control, amelioration, or reduction of risk of the aforementioned diseases, disorders and conditions in combination with other agents.
  • the compounds of the present invention may be used in combination with one or more other drugs in the treatment, prevention, control, amelioration, or reduction of risk of diseases or conditions for which compounds of the present invention or the other drugs may have utility, where the combination of the drugs together are safer or more effective than either drug alone.
  • Such other drug(s) may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of the present invention.
  • a pharmaceutical composition in unit dosage form containing such other drugs and the compound of the present invention may be desirable.
  • the combination therapy may also include therapies in which the compound of the present invention and one or more other drugs are administered on different overlapping schedules.
  • the compounds of the present invention and the other active ingredients may be used in lower doses than when each is used singly.
  • the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to a compound of the present invention.
  • the above combinations include combinations of a compound of the present invention not only with one other active compound, but also with two or more other active compounds.
  • compounds of the present invention may be used in combination with other drugs that are used in the prevention, treatment, control, amelioration, or reduction of risk of the diseases or conditions for which compounds of the present invention are useful.
  • Such other drugs may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of the present invention.
  • the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients, in addition to a compound of the present invention.
  • the weight ratio of the compound of the present invention to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used.
  • the weight ratio of the compound of the present invention to the other agent will generally range from about 1000:1 to about 1:1000, such as about 200:1 to about 1:200.
  • Combinations of a compound of the present invention and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.
  • the compound of the present invention and other active agents may be administered separately or in conjunction.
  • the administration of one element may be prior to, concurrent to, or subsequent to the administration of other agent(s).
  • the subject compounds may be used alone or in combination with other agents which are known to be beneficial in the subject indications or other drugs that affect receptors or enzymes that either increase the efficacy, safety, convenience, or reduce unwanted side effects or toxicity of the compounds of the present invention.
  • the subject compound and the other agent may be co-administered, either in concomitant therapy or in a fixed combination.
  • the subject compound may be employed in combination with anti-Alzheimer's agents, AChEis (such as Aricept (donepezil) and Exelon (rivastigmine)) and NMDA blocker Namenda (memantine), beta-secretase inhibitors, gamma-secretase inhibitors, HMG-CoA reductase inhibitors, NSAID's including ibuprofen, vitamin E, and anti-amyloid antibodies.
  • AChEis such as Aricept (donepezil) and Exelon (rivastigmine)
  • Namenda memantine
  • beta-secretase inhibitors beta-secretase inhibitors
  • gamma-secretase inhibitors gamma-secretase inhibitors
  • HMG-CoA reductase inhibitors HMG-CoA reductase inhibitors
  • NSAID's including ibuprofen, vitamin E, and anti-amyloid antibodies.
  • the subject compound may be employed in combination with sedatives, hypnotics, anxiolytics, antipsychotics, antianxiety agents, cyclopyrrolones, imidazopyridines, pyrazolopyrimidines, minor tranquilizers, melatonin agonists and antagonists, melatonergic agents, benzodiazepines, barbiturates, 5HT-2 antagonists, and the like, such as: adinazolam, allobarbital, alonimid, alprazolam, amisulpride, amitriptyline, amobarbital, amoxapine, aripiprazole, atypical antipsychotics, bentazepam, benzoctamine, brotizolam, bupropion, busprione, butabarbital, butalbital, capuride, carbocloral, chloral betaine, chloral hydrate, clomipramine, clonazepam, cloperidone,
  • the subject compound may be employed in combination with levodopa (with or without a selective extracerebral decarboxylase inhibitor such as carbidopa or benserazide), anticholinergics such as biperiden (optionally as its hydrochloride or lactate salt) and trihexyphenidyl (benzhexol) hydrochloride, COMT inhibitors such as entacapone, MAO-B inhibitors, antioxidants, A2a adenosine receptor antagonists, cholinergic agonists, NMDA receptor antagonists, serotonin receptor antagonists and dopamine receptor agonists such as alentemol, bromocriptine, fenoldopam, lisuride, naxagolide, pergolide and pramipexole.
  • levodopa with or without a selective extracerebral decarboxylase inhibitor such as carbidopa or benserazide
  • anticholinergics such as biperi
  • the dopamine agonist may be in the form of a pharmaceutically acceptable salt, for example, alentemol hydrobromide, bromocriptine mesylate, fenoldopam mesylate, naxagolide hydrochloride and pergolide mesylate.
  • a pharmaceutically acceptable salt for example, alentemol hydrobromide, bromocriptine mesylate, fenoldopam mesylate, naxagolide hydrochloride and pergolide mesylate.
  • Lisuride and pramipexol are commonly used in a non-salt form.
  • the subject compound may be employed in combination with a compound from the phenothiazine, thioxanthene, heterocyclic dibenzazepine, butyrophenone, diphenylbutylpiperidine and indolone classes of neuroleptic agent.
  • phenothiazines include chlorpromazine, mesoridazine, thioridazine, acetophenazine, fluphenazine, perphenazine and trifluoperazine.
  • Suitable examples of thioxanthenes include chlorprothixene and thiothixene.
  • An example of a dibenzazepine is clozapine.
  • An example of a butyrophenone is haloperidol.
  • An example of a diphenylbutylpiperidine is pimozide.
  • An example of an indolone is molindolone.
  • Other neuroleptic agents include loxapine, sulpiride and risperidone.
  • the neuroleptic agents when used in combination with the subject compound may be in the form of a pharmaceutically acceptable salt, for example, chlorpromazine hydrochloride, mesoridazine besylate, thioridazine hydrochloride, acetophenazine maleate, fluphenazine hydrochloride, flurphenazine enathate, fluphenazine decanoate, trifluoperazine hydrochloride, thiothixene hydrochloride, haloperidol decanoate, loxapine succinate and molindone hydrochloride.
  • a pharmaceutically acceptable salt for example, chlorpromazine hydrochloride, mesoridazine besylate, thioridazine hydrochloride, acetophenazine maleate, fluphenazine hydrochloride, flurphenazine enathate, fluphenazine decanoate, trifluoperazine hydrochloride, thiothixen
  • Perphenazine, chlorprothixene, clozapine, haloperidol, pimozide and risperidone are commonly used in a non-salt form.
  • the subject compound may be employed in combination with acetophenazine, alentemol, aripiprazole, amisulpride, benzhexol, bromocriptine, biperiden, chlorpromazine, chlorprothixene, clozapine, diazepam, fenoldopam, fluphenazine, haloperidol, levodopa, levodopa with benserazide, levodopa with carbidopa, lisuride, loxapine, mesoridazine, molindolone, naxagolide, olanzapine, pergolide, perphenazine, pimozide, pramipexole, quetiapine, ris
  • the subject compound may be employed in combination with an antidepressant or anti-anxiety agent, including norepinephrine reuptake inhibitors (including tertiary amine tricyclics and secondary amine tricyclics), selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase (RIMAs), serotonin and noradrenaline reuptake inhibitors (SNRIs), corticotropin releasing factor (CRF) antagonists, ⁇ -adrenoreceptor antagonists, neurokinin-1 receptor antagonists, atypical antidepressants, benzodiazepines, 5-HT 1A agonists or antagonists, especially 5-HT 1A partial agonists, and corticotropin releasing factor (CRF) antagonists.
  • norepinephrine reuptake inhibitors including tertiary amine tricyclics and secondary amine tricyclics
  • Specific agents include: amitriptyline, clomipramine, doxepin, imipramine and trimipramine; amoxapine, desipramine, maprotiline, nortriptyline and protriptyline; fluoxetine, fluvoxamine, paroxetine and sertraline; isocarboxazid, phenelzine, tranylcypromine and selegiline; moclobemide: venlafaxine; duloxetine; aprepitant; bupropion, lithium, nefazodone, trazodone and viloxazine; alprazolam, chlordiazepoxide, clonazepam, chlorazepate, diazepam, halazepam, lorazepam, oxazepam and prazepam; buspirone, flesinoxan, gepirone and ipsapirone, and pharmaceutically acceptable salts thereof.
  • the compounds of the present invention may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implant), by inhalation spray, nasal, vaginal, rectal, sublingual, or topical routes of administration and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration.
  • the compounds of the invention are effective for use in humans.
  • administration of" and or “administering a" compound should be understood to mean providing a compound of the invention or a prodrug of a compound of the invention to the individual in need of treatment.
  • compounds of the present invention may be suitable as PET imaging agents.
  • An aspect of the invention is realized when the PET imaging compounds of the instant invention are those that affectively inhibit the PDE2 enzyme with a Ki value less than or about 0.5 nM.
  • Another aspect of the invention is realized when the compounds of the invention are enriched with 11 C or 18 F.
  • Still another aspect of the invention is realized when the compounds of Examples 1 through 212 are enriched with 11 C or 18 F.
  • Yet another aspect of the invention is realized when Examples 30, 47, 149, 89, 90.
  • composition as used herein is intended to encompass a product comprising specified ingredients in predetermined amounts or proportions, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • Such term in relation to pharmaceutical composition is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
  • compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
  • the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases.
  • the pharmaceutical compositions of the present invention encompass any composition made by mixing a compound of the present invention and a pharmaceutically acceptable carrier.
  • compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • compositions for oral use may also be presented as hard gelatin capsules wherein the active ingredients are mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil medium for example peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions, oily suspensions, dispersible powders or granules, oil-in-water emulsions, and sterile injectable aqueous or oleagenous suspension may be prepared by standard methods known in the art.
  • pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the subject compounds are further useful for use in the prevention, treatment, control, amelioration, or reduction of risk of the diseases, disorders and conditions noted herein.
  • the dosage of active ingredient in the compositions of this invention may be varied, however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained.
  • the active ingredient may be administered to patients (animals and human) in need of such treatment in dosages that will provide optimal pharmaceutical efficacy.
  • the selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment.
  • the dose will vary from patient to patient depending upon the nature and severity of disease, the patient's weight, special diets then being followed by a patient, concurrent medication, and other factors which those skilled in the art will recognize.
  • dosage levels of between 0.001 to 10 mg/kg of body weight daily are administered to the patient, e.g., humans and elderly humans.
  • the dosage range will generally be about 0.5 mg to 1.0 g per patient per day which may be administered in single or multiple doses.
  • the dosage range will be about 0.5 mg to 500 mg per patient per day; in another embodiment about 0.5 mg to 200 mg per patient per day; and in yet another embodiment about 5 mg to 50 mg per patient per day.
  • Pharmaceutical compositions of the present invention may be provided in a solid dosage formulation such as comprising about 0.5 mg to 500 mg active ingredient, or comprising about 1 mg to 250 mg active ingredient.
  • the pharmaceutical composition may be provided in a solid dosage formulation comprising about 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg or 250 mg active ingredient.
  • the compositions may be provided in the form of tablets containing 1.0 to 1000 milligrams of the active ingredient, such as 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900, and 1000 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • the compounds may be administered on a regimen of 1 to 4 times per day, such as once or twice per day.
  • Reactions used to generate the compounds of this invention are prepared by employing conditions as shown in the schemes and examples herein, as well as using other standard manipulations such as ester hydrolysis, cleavage of protecting groups, etc., as may be known in the literature or exemplified in the experimental procedures. Starting materials are made according to procedures known in the art or as illustrated herein.
  • the final product may be further modified, for example, by manipulation of substituents.
  • substituents may include, but are not limited to, reduction, oxidation, alkylation, acylation, and hydrolysis reactions which are commonly known to those skilled in the art.
  • the order of carrying out the foregoing reaction schemes may be varied to facilitate the reaction or to avoid unwanted reaction products. The following examples are provided so that the invention might be more fully understood.
  • the progress of reactions was often monitored by TLC or LC-MS.
  • the identity of the products was often confirmed by LC-MS.
  • the LC-MS was recorded using one of the following methods.
  • Another approach to prepare the compounds of this invention is to activate a 2-thiomethyl group of pyrimidinone 4 by oxidation to 2-methylsulfonyl group followed by substituting this sulfone with amine as shown in Scheme G in a one-pot procedure to give product 5.
  • this sulfone intermediate 6 can be isolated and reacted with an amine 7 in the presence of a variety of bases or without additional base to form the 2-amino compounds 5 in a variety of solvents as shown in Schemes H - N. Similar substitutions can occur using alcohols, phenols, or hydroxide as nucleophiles instead of amines (Schemes O - T).
  • Scheme U illustrates one procedure for the syntheses of amines such as 11.
  • the coupling of aryl carboxylic acid 8 and N,O -dimethylhydroxylamine hydrochloride gives Weinreb amide 9.
  • the ketone 10 is obtained by addition of a Grignard reagent RMgBr to the Weinreb amide 9.
  • the ketone 10 is converted to amine 11 via a reductive amination using Ti(OR') 4 , NH 3 and NaBH 4 .
  • Scheme V illustrates another procedure for the syntheses of amines such as 14.
  • Aryl halide 12 is converted to ketone 13 using a Heck reaction followed by hydrolysis.
  • the ketone 13 is converted to amine 14 via a reductive amination reaction using Ti(OR") 4 , NH 3 and NaBH 4 .
  • Scheme W illustrates a procedure for the syntheses of amines such as 22.
  • Disulfane compound 15 is prepared according to the methods described by Kirsch et al. in European Journal of Organic Chemistry, 2005, 14, 3095-3100 .
  • Nitrobenzene compound 16 is prepared from disulfane compound 15 by treatment with TFA and XeF 2 . Reduction of nitrobenzene compound 16 using iron and ammonium chloride forms aniline 16.
  • Aniline 17 is converted to aryl bromide 18 through a Sandmeyer reaction. Transmetalation of aryl halide 18 using a Grignard reagent followed by the addition of a Weinreb amide leads to ketone 19.
  • Scheme Y illustrates one sequence for the syntheses of amines such as 30.
  • Arylalkylketone 27 is converted to tertiary alcohol 28 via a nucleophilic addition using a Grignard reagent R'MgBr.
  • the alcohol 28 is converted to formamide 29 via a Ritter reaction using TMSCN under acidic conditions.
  • the formamide 27 is hydrolyzed under acidic conditions to afford the amine 30.
  • Scheme Z illustrates another sequence for the syntheses of ⁇ , ⁇ -disubstituted amines 32.
  • the acid 36 is converted to acyl chloride, which is converted to ketone 35 by a Grignard addition in the presence of tris(acetylacetonate)iron(III).
  • the ketone 37 is converted to amine 38 via a reductive amination using Ti(OR') 4 , NH 3 and NaBH 4 .
  • Scheme AB outlines the procedure for the synthesis the 2-methylpropan-2-ol benzyl amines 42 from commercially available ( S )-aminoesters 39 .
  • the amine is first protected as the trifluoroacetamide 40 which is then treated with an excess of Grinard reagent.
  • the trifluoroacetamide 41 can be deprotected with base to yield the desired 2-methylpropan-2-ol benzyl amine 42. In some cases, minor racemazation (5-15%) was observed and the enantiomers can be separated via chiral column chromatography.
  • the title compound was prepared from racemic 2-(methylthio)-6-oxo-N-(1-(4-(trifluoromethyl)-phenyl)-ethyl)-1,6-dihydropyrimidine-4-carboxamide obtained as described in Example 15, Method A by oxidation as described in Preparatory Example 1.
  • Table 1 The compounds in the following Table were prepared using amide coupling procedures similar to those described in Example 15 Method B and followed by oxidation described in Preparatory Example 1, except for Preparatory Example 5, where the amide coupling step was carried out using conditions described in Example 1 (Scheme A).
  • HATU 0.590 g, 1.6 mmol
  • NMP 4 mL
  • the reaction solution was stirred at 0 °C for 10 min.
  • N , O -dimethylhydroxylamine hydrochloride (0.189 g, 1.9 mmol)
  • TEA 0.54 mL, 3.9 mmol
  • the reaction suspension was stirred at room temperature for 16 h.
  • the resulting suspension was diluted with water (100 mL) and extracted with EtOAc (3 x 20 mL).
  • Methyl magnesium bromide (1.0 M in THF, 2.56 mL, 2.6 mmol) was added dropwise to a stirred solution of 4-(pentafluorothio)-2-fluoro- N -methoxy- N -methylbenzamide (0.450 g, 1.2 mmol) in THF (5 mL) at 0 °C.
  • the reaction solution was stirred at 0 °C for 2 h.
  • the resulting suspension was diluted with sat'd aqueous NH 4 Cl (40 mL) and extracted with Et 2 O (3 x 20 mL). The combined organic layers were washed with brine (50 mL), dried with anhydrous Na 2 SO 4 and filtered. The filtrate was concentrated under reduced pressure.
  • Step 5 (Z)- N -((3 - fluoro-4-((trifluoromethyl)thio)phenyl)(1-methylcyclopropyl)methylene)-2-methylpropane-2-sulfinamide
  • Aqueous sodium carbonate (2.0 M, 32.2 mL, 64.4 mmol) was added to a solution of methyl 4-bromo-3-fluorobenzoate (5.0 g, 21.5 mmol) and 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (4.69 g, 27.9 mmol) in 1,4-dioxane (150 mL) at RT.
  • the reaction mixture was purged with nitrogen 3 times, then to the mixture was added tetrakis(triphenylphosphine) palladium(0) (1.24 g, 1.1 mmol).
  • Step 1 methyl ( S )-2-(2,2,2-trifluoroacetamido)-2-(4-(trifluoromethyl)phenyl)acetate
  • Step 2 ( S )-2,2,2-trifluoro-N-(2-hydroxy-2-methyl-1-(4 (trifluoromethyl)phenyl)propyl)acetamide
  • the biphasic solution was separated and the aqueous layer washed with ethyl acetate (2 x 10 mL). The organics were combined, dried over anhydrous sodium sulfate, filtered and the filtrate concentrate to dryness under reduced pressure. The residue was taken up in 2 mL DCM and purified via prep TLC plates (2 x 1000 ⁇ M, silica gel) developing with 25% ethyl acetate in hexanes. The bands containing the product were removed from the plates and the product eluted off with ethyl acetate. The solvent was removed under reduced pressure to afford the compound as a solid.
  • Step 3 ( S )-1-amino-2-methyl-1-(4-(trifluoromethyl)phenyl)propan-2-ol
  • reaction vessel was charged with (R)-2-(methylsulfonyl)-6-oxo-N-(1-(4-(trifluoromethyl)phenyl)-ethyl)-1,6-dihydropyrimidine-4-carboxamide (30 mg, 0.077 mmol), (R)-3-fluoropyrrolidine hydrochloride (97 mg, 0.771 mmol), and anhydrous dioxane (771 ⁇ l). The reaction mixture was evacuated and purged with N 2 then following by addition of DIEA (135 ⁇ l, 0.771 mmol). The reaction mixture was stirred at 75° C overnight.
  • a microwave reaction vessel was charge with (R)-2-(methylsulfonyl)-6-oxo-N-(1-(4-(trifluoromethyl)-phenyl)ethyl)-1,6-dihydropyrimidine-4-carboxamide (30 mg, 0.077 mmol)), 3,3-difluoro-pyrrolidine hydrochloride (111 mg, 0.771 mmol), and anhydrous DMF (1541 ⁇ l), followed by addition of K 2 CO 3 (106 mg, 0.771 mmol). The reaction mixture was evacuated and purged with N 2 , then stirred at 180 °C in microwave for 30 min. The same work-up as described in Example 6 afforded the title compound. MS: 417.1 (M+1).
  • Examples 30-84 in the following table were prepared using similar conditions as described in Example 2 and Scheme B from appropriate starting materials.
  • Example Number Structure IUPAC Name Exact Mass [M+H] + 30 2-(dimethylamino)-N-[(1R)-2-methyl-1- ⁇ 4-[(trifluoromethyl)sulfanyl]phenyl ⁇ propyl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide Calc'd 415.1, found 415.0
  • Calc'd 411.2 found 411.1 32 N- ⁇ (R)-cyclopropyl[4-(difluoromethoxy)phenyl]methyl ⁇ -2-(dimethylamino)-6-oxo-1,6-
  • Examples 99-103 in the following table were prepared using similar conditions as described in Example 4 and Scheme D from appropriate starting materials.
  • Examples 104-115 in the following table were prepared using similar conditions as described in Example 5 and Scheme E from appropriate starting materials. For the last example in this Table, TBTU was used as the coupling agent instead of HBTU under otherwisely similar conditions.
  • Step 2 ( R )- and ( S )-2-(dimethylamino1-(4-(pentafluorothio)-2-fluorophenl)ethyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide.
  • Examples 131-158 in the following table were prepared using similar conditions as described in Example 10 and Scheme J from appropriate starting materials.
  • the synthesis of the amine starting material for Example 137 was described in J. Med. Chem. 2014, 57(8), 3205.
  • the reaction temperature were tailored and modified according to the structures of the reactants and can range as high as 180 °C.
  • the ratios of amine to sulfone starting materials vary from about 10 to about 25 depending on substrates.
  • Examples 159-171 in the following table were prepared using similar conditions as described in Example 13 and Scheme L from appropriate starting materials.
  • the amine starting materials for Examples 159 and 161 were prepared according to methods described in WO2006/127530 and WO2007097931.
  • the amine starting material for Example 160 can be prepared from methods described in the literature, such as Chemische Berichte, 1902, 35, 2845; Bioorg. Med. Chem. Lett., 2003, 13(23), 4173, or US 5,312,823 May 17, 1994.
  • the amine used in the substitution reaction for Example 166 was O-protected derivative (R)-3-(( tert- butyldimethylsilyl)oxy)pyrrolidine. The TBDMS protecting group was lost during the reaction in situ.
  • Examples 172-177 in table below were obtained by chiral chromatographic resolutions of racemic compounds using chiral columns specified in the table.
  • the racemates for Examples 172/173 and 176/177 have been described above.
  • the racemic cyclopropylamine starting material for Examples 674 and 675 was obtained from ASW MedChem, Inc. (New Brunswick, New Jersey, USA) with unknown relative stereochemistry. NMR studies indicated that it is mostly cis isomer.
  • the coupling reaction with the acid was carried out using conditions similar to those used for Example 2 shown in Scheme B.
  • Examples 178 to 194 in the following table were prepared using procedure described in Example 21 and Scheme S.
  • the activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluorescence polarization (FP) methodology ( Huang, W., et al., J. Biomol Screen, 2002, 7: 215 ).
  • FP fluorescence polarization
  • the compounds of the following examples had activity in reference assays by exhibiting the ability to inhibit the hydrolysis of the phosphate ester bond of a cyclic nucleotide. Any compound exhibiting a Ki (inhibitory constant) of about 50 ⁇ M or below would be considered a PDE2 inhibitor as defined herein.
  • the PDE2 inhibitory activity of the compounds of the present invention was determined in accordance with the following experimental method.
  • Rhesus PDE2A3 was amplified from rhesus macaque brain cDNA (Biochain Institute, Hayward, CA) using primers based on human PDE2A sequence (accession NM_002599.3) where the forward primer containing a Kozak consensus was 5'-gccaccatggggcaggcatgtggc-3' and the reverse primer was 5'- tcactcagcatcaaggctgca-3'.
  • Amplification with Easy-A High-Fidelity PCR cloning enzyme (Stratagene, La Jolla, CA) was 95 °C for 2 minutes followed by thirty three cycles of 95°C for 40 seconds, 52°C for 30 seconds, and 72°C for 2 minutes 48 seconds. Final extension was 72°C for 7 minutes.
  • the PCR product was TA cloned into pcDNA3.3-TOPO (Invitrogen, Carlsbad, CA) according to standard protocol. A consensus sequence was developed from multiple clones and then deposited into GenBank (EU812167).
  • AD293 cells (Stratagene, La Jolla, CA) with 70-80% confluency were transiently transfected with rhesus PDE2A3 / pcDNA3.3-TOPO using Lipofectamine 2000 according to manufacturer specifications (Invitrogen, Carlsbad, CA). Cells were harvested 48 hours post-transfection and lysed by sonication (setting 3, 10 X 5 sec pulses) in a buffer containing 20 mM HEPES pH 7.4, 1 mM EDTA and Complete Protease Inhibitor Cocktail Tablets (Roche, Indianapolis, IN). Lysate was collected by centrifugation at 75,000 x g for 20 minutes at 4°C and supernatant utilized for evaluation of PDE2 activity.
  • the fluorescence polarization assay for cyclic nucleotide phosphodiesterases was performed using an IMAP® FP kit supplied by Molecular Devices, Sunnyvale, CA (product # R8139). IMAP® technology has been applied previously to examine the effects of phosphodiesterase inhibitors ( Huang, W., et al., J. Biomol Screen, 2002, 7: 215 ). Assays were performed at room temperature in 384-well microtiter plates with an incubation volume of 20.2 ⁇ L. Solutions of test compounds were prepared in DMSO and serially diluted with DMSO to yield 8 ⁇ L of each of 10 solutions differing by 3-fold in concentration, at 32 serial dilutions per plate.
  • PDE2 inhibitor which can be any compound that is present at 5,000 times its Ki value in the assay described below, such as Bay 60-7550 (Ki- ⁇ 0.2nM) at 1 ⁇ M concentration for 100% inhibition.
  • Bay 60-7550 was obtained from Axxora via Fisher Scientific (cat# ALX-270-421-M025 / cat# NC9314773). Put another way, any compound with Ki of ⁇ 0.2 to about 2nM could be used at 1 to 10 ⁇ M. 0% of inhibition is determined by using DMSO (1% final concentrations).
  • a Labcyte Echo 555 (Labcyte, Sunnyvale, CA) is used to dispense 200 nL from each well of the titration plate to the 384 well assay plate. Ten microliters of a solution of enzyme (1/2000 final dilution from aliquots; sufficient to produce 20% substrate conversion) was added to the assay plate.
  • the enzymatic reaction is stopped by addition of 60 ⁇ L of the binding solution to each well of the assay plates and the plates are sealed and shaken for 30 seconds.
  • the plate was incubated at room temperature for at least one hour prior to determining the fluorescence polarization (FP).
  • FP fluorescence polarization
  • the parallel and perpendicular fluorescence of each well of the plate was measured using a Tecan Genios Pro plate reader (Tecan, Switzerland) or Perkin Elmer EnVisionTM plate reader (Waltham, MA).
  • mP 0 % mP ⁇ 100 % mP Imax ⁇ Imin 1 + Drug ( 10 ⁇ pK I 1 + Substrate K M nH + 100 ⁇ % ⁇ mP + 0 % mP ⁇ 100 % mP 1 ⁇ Imax
  • the median signal of the "0% inhibition controls” (0%mP) and the median signal of the "100% inhibition controls” (100%mP) are constants determined from the controls located in columns 1-2 and 23-24 of each assay plate. An apparent (K M ) for FAM-labeled cAMP of ⁇ 10 uM was used.
  • PDE10A2 enzyme was prepared from cytosolic fractions of transiently transfected HEK cells. All other PDE's were GST Tag human enzyme expressed in insect cells and were obtained from BPS Bioscience (San Diego, CA): PDE1A (Cat# 60010), human PDE2A1(Cat# 60020), PDE3A (Cat# 60030), PDE4A1A (Cat# 60040), PDE5A1 (Cat# 60050), PDE6C (Cat# 60060), PDE7A (Cat# 60070), PDE8A1 (Cat# 60080), PDE9A2 (Cat# 60090), PDE11A4 (Cat# 60110).
  • Assays for PDE 1 through 11 were performed in parallel at room temperature in 384-well microtiter plates with an incubation volume of 20.2 ⁇ L. Solutions of test compounds were prepared in DMSO and serially diluted with DMSO to yield 30 ⁇ L of each of ten solutions differing by 3-fold in concentration, at 32 serial dilutions per plate. 100% inhibition was determined by adding buffer in place of the enzyme and 0% inhibition is determined by using DMSO (1% final concentrations). A Labcyte POD 810 (Labcyte, Sunnyvale, CA) was used to dispense 200 nL from each well of the titration plate to make eleven copies of the assay plate for each titration, one copy for each PDE enzyme.
  • a solution of each enzyme (dilution from aliquots, sufficient to produce 20% substrate conversion) and a separate solution of FAM-labeled cAMP or FAM-labeled cGMP from Molecular Devices (Sunnyvale, CA, product # R7506 or cGMP#R7508), at a final concentration of 50 nM were made in the assay buffer (10 mM Tris HCl, pH 7.2, 10 mM MgCl 2 , 0.05% NaN 3 0.01% Tween-20, and 1 mM DTT). Note that the substrate for PDE2 is 50 nM FAM cAMP containing 1000 nM of cGMP.
  • the enzyme and the substrate were then added to the assay plates in two consecutive additions of 10 ⁇ L and then shaken to mix.
  • the reaction was allowed to proceed at room temperature for 60 minutes.
  • a binding solution was then made from the kit components, comprised of 80% Solution A, 20% Solution B and binding reagent at a volume of 1/600 the total binding solution.
  • the enzymatic reaction was stopped by addition of 60 ⁇ L of the binding solution to each well of the assay plate.
  • the plates were sealed and shaken for 10 seconds.
  • the plates were incubated at room temperature for one hour, then the parallel and perpendicular fluorescence was measured using a Tecan Genios Pro plate reader (Tecan, Switzerland).
  • the compounds of the following examples had activity in inhibiting the human PDE2 enzyme in the aforementioned assays with a Ki of less than about 50 ⁇ M. Many of compounds within the present invention had activity in inhibiting the human PDE2 enzyme in the aforementioned assays, with a Ki of less than about 1 ⁇ M, preferably less than or about 0.1 ⁇ M. Additional data is provided in the following Examples. Such a result is indicative of the intrinsic activity of the compounds in use as inhibitors of the PDE2 enzyme. In general, one of ordinary skill in the art would appreciate that a substance is considered to effectively inhibit PDE2 activity if it has a Ki of less than or about 1 ⁇ M, preferably less than or about 0.1 ⁇ M.
  • the present invention also includes compounds within the generic scope of the invention which possess activity as inhibitors of other phosphodiesterase enzymes.
  • P-gp P-glycoprotein
  • BA/AB ratio of greater than 2.0 ⁇ 2.5 indicates that the compound in question is a substrate of P-gp. Desirable human BA/AB ratio is less than 2.0.
  • a number of computational methods have been published to predict P-pg ratios of compounds based on chemical structure and other molecular properties. See, for example, Desai, et al. Integration of in Silico and in Vitro Tools for Scaffold Optimization during Drug Discovery: Predicting P-glycoprotein Efflux" Mol. Pharmac.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (20)

  1. Eine Verbindung, dargestellt durch die Strukturformel I:
    Figure imgb0276
     oder ein pharmazeutisch annehmbares Salz davon, wobei:
    R1 durch ein Atom anders als Kohlenstoff an das Pyrimidinon geknüpft ist und ausgewählt ist aus der Gruppe bestehend aus Halogen, -OR, O(CH2)1-3OR, O(CH2)1-3N(R)2, O(CH2)nC(R)2OR, O-(CH2)nC4-10-Heterocyclyl, O-(CH2)1-3OC6-10-Aryl, O-C6-10-Aryl, N(Rx)2, -NRC5-10-Heteroyclyl, -NRC6-10-Aryl, -NRC3-10-Cycloalkyl, SR, wobei das Alkyl, Cycloalkyl, Heterocyclyl und Aryl gegebenenfalls substituiert sind mit ein bis drei Gruppen Ra,
    R1a H oder C1-6-Alkyl bedeutet, wobei das Alkyl gegebenenfalls mit OH oder Halogen substituiert ist,
    R2 und R3 unabhängig ausgewählt sind aus der Gruppe bestehend aus Wasserstoff, C1-6-Alkyl, (CH2)nCN, C(O)R, C(O)OR, CF3, -C3-10-Cycloalkyl, C6-10-Aryl, C5-10-Heteroaryl, wobei das Alkyl, Cycloalkyl, Aryl und Heteroaryl gegebenenfalls substituiert sind mit ein bis drei Gruppen Rb,
    R2 und R3 sich mit dem Kohlenstoffatom, an das sie gebunden sind, unter Bildung eines C3-6-Cycloalkyls vereinen können, wobei das Cycloalkyl gegebenenfalls mit 1-2 Heteroatomen, ausgewählt aus O, S und N, unterbrochen ist und gegebenenfalls mit ein bis drei Gruppen Rb substituiert ist,
    R4 Wasserstoff, Halogen oder C1-6-Alkyl bedeutet, oder, alternativ,
    R2 und R3 sich mit dem Kohlenstoffatom, an das sie gebunden sind, und dem R4 am Phenylring vereinen können unter Bildung eines bicyclischen C6-10-Rings, der den Phenylring beinhaltet, wobei der bicyclische Ring gegebenenfalls mit 1-2 Heteroatomen, ausgewählt aus O, S und N, unterbrochen ist und gegebenenfalls mit ein bis drei Gruppen Rb substituiert ist,
    R H oder C1-6-Alkyl bedeutet,
    Ra ausgewählt ist aus der Gruppe bestehend aus H, Halogen, CN, C1-6-Alkyl, (CH2)nOR, (O)pC1-4-Halogenalkyl, S(O)SCF3, S(O)SR, SF5, C3-10-Cycloalkyl, wobei das Alkyl und Cycloalkyl gegebenenfalls mit ein bis drei Gruppen Rb substituiert sind,
    Rb ausgewählt ist aus der Gruppe bestehend aus H, Halogen, C1-6-Alkyl, SO2C1-6-Alkyl und C1-4-Halogenalkyl,
    jedes Vorkommen von RX unabhängig H oder C1-6-Alkyl bedeutet, oder zwei benachbarte RX-Gruppen sich mit dem Stickstoffatom, an das sie gebunden sind, vereinen können unter Bildung eines C4-10-Heterocyclyls, gegebenenfalls substituiert mit ein bis drei Gruppen Rb,
    n 0, 1, 2, 3 oder 4 bedeutet,
    s 0, 1 oder 2 bedeutet und
    p 0 oder 1 bedeutet.
  2. Die Verbindung gemäß Anspruch 1 oder ein pharmazeutisch annehmbares Salz davon, wobei R1a Wasserstoff ist.
  3. Die Verbindung gemäß einem der Ansprüche 1-2 oder ein pharmazeutisch annehmbares Salz davon, wobei R1 ausgewählt ist aus der Gruppe bestehend aus OR, O(CH2)1-3OR, O(CH2)nC(R)2OR und O(CH2)1-3N(R)2 und gegebenenfalls substituiertem O-(CH2)nC4-10-Heterocyclyl, wobei das Heterocyclyl ausgewählt ist aus der Gruppe bestehend aus Oxetanyl, Tetrahydrofuranyl, Piperidinyl, Pyrrolidinyl, Morpholinyl, Dihydropyrrolopyrazolyl, Dihydropyrrolopyrimidyl, Tetrahydropyranyl, Pyrazolyl und Azetidinyl.
  4. Die Verbindung gemäß einem der Ansprüche 1-2 oder ein pharmazeutisch annehmbares Salz davon, wobei R1 ausgewählt ist aus der Gruppe N(RX)2, -NRC5-10-Heterocyclyl, -NRC6-10-Aryl und -NRC3-10-Cycloalkyl, wobei das Cycloalkyl, Aryl und Heterocyclyl gegebenenfalls mit ein bis drei Gruppen Ra substituiert sind.
  5. Die Verbindung gemäß einem der Ansprüche 1-2 oder ein pharmazeutisch annehmbares Salz davon, wobei R1 N(RX)2 ist und die zwei benachbarten RX-Gruppen mit dem Stickstoffatom, an das sie gebunden sind, vereint sind unter Bildung eines C4-10-Heterocyclyl, ausgewählt aus der Gruppe bestehend aus gegebenenfalls substituiertem Pyrrolidinyl, Pyrazolyl, Azetidinyl, Piperidinyl, Morpholinyl, Dihydropyrrolopyrazolyl, Dihydropyrrolopyrimidinyl und Dihydropyrrolopyridinyl.
  6. Die Verbindung gemäß einem der Ansprüche 1-2 oder ein pharmazeutisch annehmbares Salz davon, wobei R1 O-(CH2)nC4-10-Heterocycyl ist, wobei das Heterocyclyl gegebenenfalls mit ein bis drei Gruppen Ra substituiert ist.
  7. Die Verbindung gemäß einem der Ansprüche 1-6 oder ein pharmazeutisch annehmbares Salz davon, wobei R1 ausgewählt ist aus der Gruppe bestehend aus SCH3, -N(CH3)2, N(CH3)(CH2CH3), N(CH2CH3)2, -NH2, -NHCH3, -NH-Cyclobutyl, NH-Cyclopentyl, NH-Cyclopropyl, NH-Pyridyl, -OR, -O-Phenyl, -O(CH2)2OCH3, -O(CH2)3OCH3, -O(CH2)3OCH(CH3)2, -O(CH2)2N(CH3)2, -O(CH2)2C(CH3)2OCH3, -OCH2-Oxetanyl, -O(CH2)4OCH3, -O(CH2)3NHCH3, -O-Tetrahydrofuranyl, -O-Piperidinyl, -O-Oxetanyl, -O(CH2)3O-Phenyl, O(CH2)2CH(CH3)OCH3, -O-Tetrahydropyranyl, O-Pyrrolidinyl, N-verknüpftes Pyrazolyl, N-verknüpftes Azetidinyl, N-verknüpftes Pyrrolidinyl und N-verknüpftes Piperidinyl, wobei das Cyclobutyl, Cyclopentyl, Cyclopropyl, Phenyl, Oxetanyl, Tetrahydrofuranyl, Piperidinyl, Tetrahydropyranyl, Pyrrolidinyl, Pyrazolyl und Azetidinyl gegebenenfalls mit ein bis drei Gruppen Ra substituiert sind.
  8. Die Verbindung gemäß einem der Ansprüche 1, 2, 4 und 7 oder ein pharmazeutisch annehmbares Salz davon, wobei R1 ausgewählt ist aus N(CH3)2, N(CH3)(CH2CH3), N(CH2CH3)2, -NH2, -NHCH3 und gegebenenfalls substituiertem NH-Cyclobutyl, NH-Cyclopentyl, NH-Cyclopropyl und NH-Pyridyl.
  9. Die Verbindung gemäß einem der Ansprüche 1, 2, 4, 6 und 8 oder ein pharmazeutisch annehmbares Salz davon, wobei R1 ausgewählt ist aus N(CH3)2.
  10. Die Verbindung gemäß einem der Ansprüche 1-9 oder ein pharmazeutisch annehmbares Salz davon, wobei eines von R2 und R3 Wasserstoff oder CH3 ist und das andere C1-6-Alkyl oder C3-10-Cycloalkyl ist, wobei das Alkyl und Cycloalkyl gegebenenfalls mit ein bis drei Gruppen Rb substituiert sind.
  11. Die Verbindung gemäß Anspruch 10 oder ein pharmazeutisch annehmbares Salz davon, wobei das Alkyl ausgewählt ist aus der Gruppe bestehend aus CH3, CH(CH3)2, CH2CH3, C(CH3)3, und das gegebenenfalls substituierte Cycloalkyl ausgewählt ist aus Cyclopropyl, Cyclobutyl und Cyclopentyl.
  12. Die Verbindung gemäß einem der Ansprüche 10-11 oder ein pharmazeutisch annehmbares Salz davon, wobei das Alkyl ausgewählt ist aus der Gruppe bestehend aus CH3, CH(CH3)2 und CH2CH3, und das gegebenenfalls substituierte Cycloalkyl Cyclopropyl ist.
  13. Die Verbindung gemäß einem der Ansprüche 1-9 oder ein pharmazeutisch annehmbares Salz davon, wobei R2 und R3 mit dem Kohlenstoffatom, an das sie gebunden sind, vereint sind unter Bildung eines C3-10-Cycloalkyls, wobei das Cycloalkyl gegebenenfalls mit ein bis drei Gruppen Rb substituiert ist.
  14. Die Verbindung gemäß Anspruch 13, wobei das Cycloalkyl ausgewählt ist aus der Gruppe bestehend aus Cyclopropyl, Cyclobutyl und Cyclopentyl.
  15. Die Verbindung gemäß einem der Ansprüche 1-14 oder ein pharmazeutisch annehmbares Salz davon, wobei Ra ausgewählt ist aus OH, Halogen, CH3, gegebenenfalls substituiertem Cyclopropyl, (CH2)nOCH3, CH2F, (CH2)nCF3, OCHF2, OCF3, SCH3, SCF3, SF5, SOCF3, SO2CF3, SO2CH3, CH2NH2 und (CH2)nN(CH3)2.
  16. Die Verbindung gemäß einem der Ansprüche 1-12 und 15 oder ein pharmazeutisch annehmbares Salz davon, dargestellt durch Strukturformel II:
    Figure imgb0277
     wobei R1 ausgewählt ist aus der Gruppe bestehend aus -N(CH3)2, NH2, NHCH3, O(CH2)3NHCH3 und gegebenenfalls substituiertem O-Tetrahydrofuranyl, N-verknüpftem Pyrazolyl, N-verknüpftem Pyrrolidinyl, O-Pyrrolidinyl oder O-Piperidinyl, R3 ausgewählt ist aus der Gruppe bestehend aus CH3, CH(CH3)2, CH2CH3, C(CH3)3 und gegebenenfalls substituiertem Cyclopropyl, und Ra ausgewählt ist aus der Gruppe bestehend aus SCF3, CF3, OCF2, OCF3 und CH2CF3.
  17. Eine Verbindung gemäß Anspruch 1, die ist:
    N-(1-(3-Fluor-4-(trifluormethyl)phenyl)cyclopropyl)-6-oxo-2-(pyrrolidin-1-yl)-1,6-dihydropyrimidin-4-carboxamid,
    (R)-N-(2,2-Dimethyl-1-(4-(trifluormethyl)phenyl)propyl)-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    (R)-N-(1-(3-Chlor-4-(trifluormethoxy)phenyl)ethyl)-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    (R)-N-(Cyclopropyl(4-(pentafluor-λ6-sulfanyl)phenyl)methyl)-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    (R)-2-(Dimethylamino)-6-oxo-N-(1-(4-(pentafluor-λ6-sulfanyl)phenyl)propyl)-1,6-dihydropyrimidin-4-carboxamid,
    (R)-6-Oxo-2-(pyrrolidin-1-yl)-N-(1-(4-(trifluormethyl)phenyl)ethyl)-1,6-dihydropyrimidin-4-carboxamid,
    (R)-2-(4-Methyl-1H-pyrazol-1-yl)-6-oxo-N-(1-(4-(trifluormethyl)phenyl)ethyl)-1,6-dihydropyrimidin-4-carboxamid,
    (R)-2-(3-Methyl-1H-pyrazol-1-yl)-6-oxo-N-(1-(4-(trifluormethyl)phenyl)ethyl)-1,6-dihydropyrimidin-4-carboxamid,
    (R)-6-Oxo-2-(1H-pyrazol-1-yl)-N-(1-(4-(trifluormethyl)phenyl)ethyl)-1,6-dihydropyrimidin-4-carboxamid,
    (R)-2-(Azetidin-1-yl)-6-oxo-N-(1-(4-(trifluormethyl)phenyl)ethyl)-1,6-dihydropyrimidin-4-carboxamid,
    2-((R)-3-Fluorpyrrolidin-1-yl)-6-oxo-N-((R)-1-(4-(trifluormethyl)phenyl)ethyl)-1,6-dihydropyrimidin-4-carboxamid,
    2-((S)-3-Fluorpyrrolidin-1-yl)-6-oxo-N-((R)-1-(4-(trifluormethyl)phenyl)ethyl)-1,6-dihydropyrimidin-4-carboxamid,
    (R)-2-(3,3-Difluorpyrrolidin-1-yl)-6-oxo-N-(1-(4-(trifluormethyl)phenyl)ethyl)-1,6-dihydropyrimidin-4-carboxamid,
    N-((R)-2,2-Dimethyl-1-(4-(trifluormethyl)phenyl)propyl)-2-(3-(methoxymethyl)-pyrrolidin-1-yl)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    (R)-2-(Methylthio)-6-oxo-N-(1-(4-(trifluormethyl)phenyl)ethyl)-1,6-dihydropyrimidin-4-carboxamid,
    (S)-2-(Methylthio)-6-oxo-N-(1-(4-(trifluormethyl)phenyl)ethyl)-1,6-dihydropyrimidin-4-carboxamid,
    (R)-2-Methoxy-6-oxo-N-(1-(4-(trifluormethyl)phenyl)ethyl)-1,6-dihydropyrimidin-4-carboxamid,
    (R)-2-Ethoxy-6-oxo-N-(1-(4-(trifluormethyl)phenyl)ethyl)-1,6-dihydropyrimidin-4-carboxamid,
    (R)-6-Oxo-2-phenoxy-N-(1-(4-(trifluormethyl)phenyl)ethyl)-1,6-dihydropyrimidin-4-carboxamid,
    (R)-2-Hydroxy-N-(2-methyl-1-(4-((trifluormethyl)thio)phenyl)propyl)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(2-Methoxyethoxy)-6-oxo-N-(1-(4-(trifluormethyl)phenyl)ethyl)-1,6-dihydropyrimidin-4-carboxamid,
    (R)-2-(3,4-Dimethoxyphenoxy)-6-oxo-N-(1-(4-(trifluormethyl)phenyl)ethyl)-1,6-dihydropyrimidin-4-carboxamid,
    2-(3-Fluorazetidin-1-yl)-6-oxo-N-{(1R)-1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-(3,3-Difluorazetidin-1-yl)-6-oxo-N-{(1R)-1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    N-{(R)-Cyclopropyl[3-fluor-4-(trifluormethoxy)phenyl]methyl}-6-oxo-2-pyrrolidin-1-yl-1,6-dihydropyrimidin-4-carboxamid,
    N-{(R)-Cyclopropyl[4-(trifluormethyl)phenyl]methyl}-6-oxo-2-pyrrolidin-1-yl-1,6-dihydropyrimidin-4-carboxamid,
    N-[(R)-Cyclopropyl{4-[(trifluormethyl)sulfanyl]phenyl}methyl]-6-oxo-2-pyrrolidin-1-yl-1,6-dihydropyrimidin-4-carboxamid,
    6-Oxo-2-pyrrolidin-1-yl-N-{(1R)-1-[4-(trifluormethoxy)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    N-[(1R)-1-{3-Fluor-4-[(trifluormethyl)sulfanyl]phenyl}propyl]-6-oxo-2-pyrrolidin-1-yl-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-[(1R)-2-methyl-1-{4-[(trifluormethyl)sulfanyl]phenyl}propyl]-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{(1R)-2,2-dimethyl-1-[4-(2,2,2-trifluorethyl)phenyl]propyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(R)-Cyclopropyl[4-(difluormethoxy)phenyl]methyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-1-[4-(Difluormethoxy)phenyl]-2-methylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-1-[4-(Difluormethoxy)phenyl]-2,2-dimethylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-[(1R)-1-(4-Cyclopropylphenyl)-2,2-dimethylpropyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-1-[2,5-Difluor-4-(trifluormethyl)phenyl]ethyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{(1R)-1-[2-fluor-4-(trifluormethyl)phenyl]-2,2-dimethylpropyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{(1R)-2,2-dimethyl-1-[4-(pentafluor-λ6-sulfanyl)phenyl]propyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{1,2-dimethyl-1-[4-(pentafluor-λ6-sulfanyl)phenyl]propyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-[(1R)-1-(4-Cyclopropyl-3-fluorphenyl)ethyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-[(R)-[3-fluor-4-(trifluormethyl)phenyl](1-methylcyclopropyl)-methyl]-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{(R)-(1-methylcyclopropyl)[4-(trifluormethyl)phenyl]methyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-[(R)-(4-tert-Butylphenyl)(1-methylcyclopropyl)methyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-6-oxo-N-{1-[4-(pentafluor-λ6-sulfanyl)phenyl]cyclopropyl}-1,6-dihydropyrimidin-4-carboxamid,
    N-[1-(4-tert-Butylphenyl)cyclopropyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{(1R)-2-methyl-1-[4-(trifluormethyl)phenyl]propyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-1-[4-(Difluormethoxy)-3-fluorphenyl]-2-methylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{1-[2-fluor-4-(trifluormethyl)phenyl]cyclopropyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-[1-(4-tert-Butoxyphenyl)cyclopropyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-6-oxo-N-{1-[4-(2,2,2-trifluorethyl)phenyl]cyclopropyl}-1,6-dihydropyrimidin-4-carboxamid,
    N-{1-[4-(Difluormethoxy)phenyl]cyclopropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(R)-Cyclopropyl[4-(difluormethoxy)-3-fluorphenyl]methyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-1-[4-(Difluormethoxy)-3-fluorphenyl]-2,2-dimethylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-[(R)-[4-(Difluormethoxy)-3-fluorphenyl](1-methylcyclopropyl)methyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-[(R)-Cyclopropyl(4-cyclopropyl-3-fluorphenyl)methyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{(R)-(1-methylcyclopropyl)[4-(pentafluor-λ6-sulfanyl)phenyl]methyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-[(1R)-1-(4-Cyclopropyl-3-fluorphenyl)-2,2-dimethylpropyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-[(R)-[4-(Difluormethyl)-3-fluorphenyl](1-methylcyclopropyl)methyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-1-[4-(Difluormethyl)phenyl]-2,2-dimethylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-[(R)-[4-(Difluormethyl)phenyl](1-methylcyclopropyl)methyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-1-[4-(Difluormethyl)-3-fluorphenyl]-2,2-dimethylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-1-[4-(Difluormethyl)phenyl]-2-methylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(R)-Cyclopropyl[4-(difluormethyl)phenyl]methyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-1-[4-(Difluormethyl)-3-fluorphenyl]-2-methylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(R)-Cyclopropyl[4-(difluormethyl)-3-fluorphenyl]methyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-1-[4-(Difluormethyl)phenyl]propyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-1-[4-(Difluormethyl)-3-fluorphenyl]propyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{1-[4-(Difluormethyl)-3-fluorphenyl]-1-methylethyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{1-[4-(Difluormethyl)-3-fluorphenyl]cyclopropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-[(R)-(4-Cyclopropylphenyl)(1-methylcyclopropyl)methyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{(1S)-2,2-dimethyl-1-[4-(trifluormethyl)phenyl]propyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-1-[4-(Difluormethyl)-2-fluorphenyl]-2,2-dimethylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-1-[4-(1,1-Difluorethyl)phenyl]ethyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-1-[4-(1,1-Difluorethyl)phenyl]-2-methylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-1-[4-(1,1-Difluorethyl)phenyl]-2,2-dimethylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-1-[4-(1,1-Difluorethyl)-3-fluorphenyl]-2-methylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{1-methyl-1-[2-methyl-4-(trifluormethyl)phenyl]ethyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{1-[2-methoxy-4-(trifluormethyl)phenyl]-1-methylethyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{1-[2-Chlor-4-(trifluormethyl)phenyl]-1-methylethyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{1-[2-fluor-4-(trifluormethoxy)phenyl]-1-methylethyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{1-[2-fluor-4-(trifluormethyl)phenyl]-1-methylethyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{(1R)-1-[2-fluor-4-(trifluormethoxy)phenyl]ethyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-1-[2,3-Difluor-4-(trifluormethyl)phenyl]ethyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-[(R)-[3-Chlor-4-(trifluormethoxy)phenyl](cyclopropyl)methyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-1-[3-Chlor-4-(trifluormethoxy)phenyl]-2-methylpropyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-6-oxo-N-{(1R)-1-[4-(trifluormethoxy)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-6-oxo-N-[(1R)-1-{4-[(trifluormethyl)sulfanyl]phenyl}propyl]-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-6-oxo-N-{(1R)-1-[4-(pentafluor-λ6-sulfanyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{(1R)-1-[3-fluor-4-(trifluormethoxy)phenyl]ethyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{(1R)-2-methyl-1-[4-(trifluormethoxy)phenyl]propyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-6-oxo-N-(1-{4-[(trifluormethyl)sulfanyl]phenyl}cyclopropyl)-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{1-[3-fluor-4-(trifluormethyl)phenyl]-1-methylethyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{1-[3-fluor-4-(trifluormethyl)phenyl]cyclopropyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-2-Methyl-1-[4-(trifluormethyl)phenyl]propyl}-6-oxo-2-pyrrolidin-1-yl-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-[(1R)-1-{3-fluor-4-[(trifluormethyl)sulfanyl]phenyl}ethyl]-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-[(R)-Cyclopropyl{3-fluor-4-[(trifluormethyl)sulfanyl]phenyl}methyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-[(1R)-1-{3-fluor-4-[(trifluormethyl)sulfanyl]phenyl}propyl]-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(R)-Cyclopropyl[4-(pentafluor-λ6-Sulfanyl)phenyl]methyl}-6-oxo-2-pyrrolidin-1-yl-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{(1R)-2,2-dimethyl-1-[4-(trifluormethoxy)phenyl]propyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{(1R)-1-[3-fluor-4-(trifluormethoxy)phenyl]-2,2-dimethylpropyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{(1R)-1-[3-fluor-4-(trifluormethyl)phenyl]-2,2-dimethylpropyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-[(1R)-2,2-dimethyl-1-{4-[(trifluormethyl)sulfanyl]phenyl}propyl]-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{(1R)-1-[3-fluor-4-(trifluormethoxy)phenyl]propyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-6-oxo-N-{(1R)-1-[4-(trifluormethoxy)phenyl]propyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{(1R)-1-[3-fluor-4-(trifluormethyl)phenyl]propyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(R)-Cyclopropyl[4-(trifluormethoxy)phenyl]methyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(R)-Cyclopropyl[4-(trifluormethyl)phenyl]methyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(R)-Cyclopropyl[3-fluor-4-(trifluormethyl)phenyl]methyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(R)-Cyclopropyl[3-fluor-4-(trifluormethoxy)phenyl]methyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-[(R)-Cyclopropyl{4-[(trifluormethyl)sulfanyl]phenyl}methyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{(1R)-1-[3-fluor-4-(trifluormethyl)phenyl]-2-methylpropyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-[(R)-Cyclopropyl(4-cyclopropylphenyl)methyl]-6-oxo-2-pyrrolidin-1-yl-1,6-dihydropyrimidin-4-carboxamid,
    N-{(R)-Cyclopropyl[4-(trifluormethoxy)phenyl]methyl}-6-oxo-2-pyrrolidin-1-yl-1,6-dihydropyrimidin-4-carboxamid,
    N-[(R)-Cyclopropyl(4-cyclopropylphenyl)methyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    (R)-2-(Dimethylamino)-N-(1-(4-(pentafluorthio)-2-fluorphenyl)ethyl)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    (S)-2-(Dimethylamino)-N-(1-(4-(pentafluorthio)-2-fluorphenyl)ethyl)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{1-methyl-1-[4-(pentafluor-λ6-sulfanyl)phenyl]ethyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    (S)-2-(Dimethylamino)-N-[{3-fluor-4-[(trifluormethyl)sulfanyl]phenyl}(1-methylcyclopropyl)methyl]-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    (R)-2-(Dimethylamino)-N-[{3-fluor-4-[(trifluormethyl)sulfanyl]phenyl}(1-methylcyclopropyl)methyl]-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    (S)-2-(Dimethy!amino)-6-oxo-N-{1-[4-(2,2,2-trifluor-1,1-dimethylethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    (R)-2-(Dimethylamino)-6-oxo-N-{1-[4-(2,2,2-trifluor-1,1-dimethylethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    (S)-2-(Dimethylamino)-N-{1-[3-fluor-4-(1-methylcyclopropyl)phenyl]-2,2-dimethylpropyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    (R)-2-(Dimethylamino)-N-{1-[3-fluor-4-(1-methylcyclopropyl)phenyl]-2,2-dimethylpropyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    (S)-2-(Dimethylamino)-6-oxo-N-[1-{4-[1-(trifluormethyl)cyclopropyl]phenyl}ethyl]-1,6-dihydropyrimidin-4-carboxamid,
    (R)-2-(Dimethy!amino)-6-oxo-N-[1-{4-[1-(trifluormethyl)cyclopropyl]phenyl}ethyl]-1,6-dihydropyrimidin-4-carboxamid,
    (S)-2-(Dimethylamino)-N-{1-[2-fluor-4-(pentafluor-λ6-sulfanyl)phenyl]-2,2-dimethylpropyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    (R)-2-(Dimethylamino)-N-{1-[2-fluor-4-(pentafluor-λ6-sulfanyl)phenyl]-2,2-dimethylpropyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    (S)-2-(Dimethylamino)-N-{1-[2-fluor-4-(trifluormethyl)phenyl]-1-methylpropyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    (R)-2-(Dimethylamino)-N-{1-[2-fluor-4-(trifluormethyl)phenyl]-1-methylpropyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    6-Oxo-2-piperidin-1-yl-N-{(1R)-1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-Morpholin-4-yl-6-oxo-N-{(1R)-1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-6-oxo-N-{(1R)-1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-Amino-6-oxo-N-{(1R)-1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-(Methylamino)-6-oxo-N-{(1R)-1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    6-Oxo-2-(pyridin-2-ylamino)-N-{(1R)-1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-[2-(Methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]-6-oxo-N-{(1R)-1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-(Cyclobutylamino)-6-oxo-N-{(1R)-1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-(Cyclopentylamino)-6-oxo-N-{(1R)-1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-(Cyclopropylamino)-6-oxo-N-{(1R)-1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-[Ethyl(methyl)amino]-6-oxo-N-{(1R)-1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-(Diethylamino)-6-oxo-N-{(1R)-1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-6-oxo-N-[(1R)-1-{4-[(trifluormethyl)sulfanyl]phenyl}ethyl]-1,6-dihydropyrimidin-4-carboxamid,
    2-(Methylamino)-6-oxo-N-[(1R)-1-{4-[(trifluormethyl)sulfanyl]phenyl}ethyl]-1,6-dihydropyrimidin-4-carboxamid,
    2-Amino-6-oxo-N-[(1R)-1-{4-[(trifluormethyl)sulfanyl]phenyl}ethyl]-1,6-dihydropyrimidin-4-carboxamid,
    6-Oxo-2-pyrrolidin-1-yl-N-[(1R)-1-{4-[(trifluormethyl)sulfanyl]phenyl}ethyl]-1,6-dihydropyrimidin-4-carboxamid,
    N-[(1R)-2-Methyl-1-{4-[(trifluormethyl)sulfanyl]phenyl}propyl]-6-oxo-2-pyrrolidin-1-yl-1,6-dihydropyrimidin-4-carboxamid,
    2-Azetidin-1-yl-N-[(1 R)-2-methyl-1-{4-[(trifluormethyl)sulfanyl]phenyl}propyl]-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{(1R)-1-[3-fluor-4-(trifluormethoxy)phenyl]-2-methylpropyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-[(1R)-1-{3-fluor-4-[(trifluormethyl)sulfanyl]phenyl}-2-methylpropyl]-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-1-[3-Fluor-4-(trifluormethoxy)phenyl]-2-methylpropyl}-2-(methylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-Amino-N-{(1R)-1-[3-fluor-4-(trifluormethoxy)phenyl]-2-methylpropyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Methylamino)-N-[(1R)-2-methyl-1-{4-[(trifluormethyl)sulfanyl]phenyl}propyl]-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-Amino-N-[(1R)-2-methyl-1-{4-[(trifluormethyl)sulfanyl]phenyl}propyl]-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-[(1R)-1-{3-Fluor-4-[(trifluormethyl)sulfanyl]phenyl}-2-methylpropyl]-2-(methylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-Amino-N-[(1R)-1-{3-fluor-4-[(trifluormethyl)sulfanyl]phenyl}-2-methylpropyl]-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-Amino-N-{(1R)-2,2-dimethyl-1-[4-(trifluormethyl)phenyl]propyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-2,2-Dimethyl-1-[4-(trifluormethyl)phenyl]propyl}-2-(methylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(2-Methyl-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl)-6-oxo-N-{(1R)-1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-(1,3-Dihydro-2H-pyrrolo[3,4-c]pyridin-2-yl)-6-oxo-N-{(1R)-1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-(5,7-Dihydro-6H-pyrrolo[3,4-d]pyrimidin-6-yl)-6-oxo-N-{(1R)-1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-[(3S)-3-Fluorpyrrolidin-1-yl]-N-{(1R)-1-[3-fluor-4-(trifluormethoxy)phenyl]-2-methylpropyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-[(3R)-3-Fluorpyrrolidin-1-yl]-N-{(1R)-1-[3-fluor-4-(trifluormethoxy)phenyl]-2-methylpropyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(3-Fluorazetidin-1-yl)-N-{(1R)-1-[3-fluor-4-(trifluormethoxy)phenyl]-2-methylpropyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-[(3S)-3-Fluorpyrrolidin-1-yl]-N-[(1R)-1-{3-fluor-4-[(trifluormethyl)sulfanyl]phenyl}-2-methylpropyl]-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-1-[3-Fluor-4-(trifluormethoxy)phenyl]-2-methylpropyl}-2-[(3R)-3-hydroxypyrrolidin-1-yl]-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(R)-Cyclopropyl[4-(trifluormethyl)phenyl]methyl}-2-[(3S)-3-fluorpyrrolidin-1-yl]-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-[(3S)-3-Fluorpyrrolidin-1-yl]-N-{(1R)-1-[3-fluor-4-(trifluormethyl)phenyl]-2-methylpropyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-2,2-Dimethyl-1-[4-(trifluormethyl)phenyl]propyl}-2-[(3S)-3-fluorpyrrolidin-1-yl]-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-2,2-Dimethyl-1-[4-(trifluormethyl)phenyl]propyl}-2-[(3S)-3-methoxypyrrolidin-1-yl]-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    N-{(1R)-2,2-Dimethyl-1-[4-(trifluormethyl)phenyl]propyl}-2-[(3R)-3-methoxypyrrolidin-1-yl]-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    (R)-2-(Dimethylamino)-N-{1,2-dimethyl-1-[4-(pentafluor-λ6-sulfanyl)phenyl]propyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    (S)-2-(Dimethylamino)-N-{1,2-dimethyl-1-[4-(pentafluor-λ6-sulfanyl)phenyl]propyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-N-{2-methyl-1-[4-(trifluormethyl)phenyl]cyclopropyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid (cis, Enantiomer A),
    2-(Dimethylamino)-N-{2-methyl-1-[4-(trifluormethyl)phenyl]cyclopropyl}-6-oxo-1,6-dihydropyrimidin-4-carboxamid(cis, Enantiomer B),
    (R)-N-{(1R)-2,2-Dimethyl-1-[4-(trifluormethyl)phenyl]propyl}-2-[3-(methoxymethyl)pyrrolidin-1-yl]-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    (S)-N-{(1R)-2,2-Dimethyl-1-[4-(trifluormethyl)phenyl]propyl}-2-[3-(methoxymethyl)pyrrolidin-1-yl]-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    6-Oxo-2-propoxy-N-{(1R)-1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-(3-Methoxypropoxy)-6-oxo-N-{1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-[(1-Methylpiperidin-3-yl)oxy]-6-oxo-N-{1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-[3-(1-Methylethoxy)propoxy]-6-oxo-N-{1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-(3-Methoxy-3-methylbutoxy)-6-oxo-N-{1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-[2-(Methylamino)ethoxy]-6-oxo-N-{1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    6-Oxo-2-(tetrahydrofuran-3-yloxy)-N-{1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-[3-(4-Methoxyphenoxy)propoxy]-6-oxo-N-{1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    N-[(1R)-1-(4-Cyclopropyl-3-fluorphenyl)-2-methylpropyl]-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-6-oxo-N-{phenyl[4-(trifluormethyl)phenyl]methyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-6-oxo-N-{pyridin-4-yl[4-(trifluormethyl)phenyl]methyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-6-oxo-N-{2-oxo-1-[4-(trifluormethyl)phenyl]propyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-6-oxo-N-[(4R)-7-(trifluormethyl)-3,4-dihydro-1H-isochromen-4-yl]-1,6-dihydropyrimidin-4-carboxamid,
    N-{Cyano[4-(trifluormethyl)phenyl]methyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-6-oxo-N-{1-[4-(trifluormethoxy)phenyl]cyclobutyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-6-oxo-N-{1-[4-(trifluormethyl)phenyl]cyclopentyl}-1,6-dihydropyrimidin-4-carboxamid,
    N-{2-Cyano-1-[4-(trifluormethyl)phenyl]ethyl}-2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-6-oxo-N-[(1S)-6-(trifluormethyl)-1,2,3,4-tetrahydronaphthalin-1-yl]-1,6-dihydropyrimidin-4-carboxamid,
    Methyl-({[2-(dimethylamino)-6-oxo-1,6-dihydropyrimidin-4-yl]carbonyl}amino)[4-(trifluormethyl)phenyl]acetate,
    2-(Dimethylamino)-6-oxo-N-{2,2,2-trifluor-1-[4-(trifluormethyl)phenyl]ethyl}-1,6-dihydropyrimidin-4-carboxamid,
    2-(Dimethylamino)-6-oxo-N-{3-[4-(trifluormethyl)phenyl]oxetan-3-yl}-1,6-dihydropyrimidin-4-carboxamid,
    oder ein pharmazeutisch annehmbares Salz davon.
  18. Eine pharmazeutische Zusammensetzung, die einen pharmazeutisch annehmbaren Träger und eine Verbindung nach einem der Ansprüche 1-17 oder ein pharmazeutisch annehmbares Salz oder Solvat davon umfasst.
  19. Eine Verbindung nach einem der Ansprüche 1-17 oder ein pharmazeutisch annehmbares Salz davon zur Verwendung in der Medizin.
  20. Eine Verbindung nach einem der Ansprüche 1-17 oder ein pharmazeutisch annehmbares Salz davon zur Verwendung bei der Behandlung einer Störung, ausgewählt aus psychotischen Störungen, wahnhaften Störungen und medikamenteninduzierten Psychosen, Angststörungen, Bewegungsstörungen, Gemütsstörungen, Alzheimer-Krankheit, Schizophrenie, Migränen, Parkinson-Krankheit, Parkinson-Demenz und neurodegenerativen Störungen.
EP16796942.7A 2015-05-15 2016-05-10 Pyrimidinonamidverbindungen als pde2-inhibitoren Active EP3294297B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2015/079091 WO2016183741A1 (en) 2015-05-15 2015-05-15 Pyrimidinone amide compounds as pde2 inhibitors
PCT/US2016/031559 WO2016186888A1 (en) 2015-05-15 2016-05-10 Pyrimidinone amide compounds as pde2 inhibitors

Publications (3)

Publication Number Publication Date
EP3294297A1 EP3294297A1 (de) 2018-03-21
EP3294297A4 EP3294297A4 (de) 2018-12-12
EP3294297B1 true EP3294297B1 (de) 2019-12-18

Family

ID=57319113

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16796942.7A Active EP3294297B1 (de) 2015-05-15 2016-05-10 Pyrimidinonamidverbindungen als pde2-inhibitoren

Country Status (3)

Country Link
US (1) US10285989B2 (de)
EP (1) EP3294297B1 (de)
WO (2) WO2016183741A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119009A1 (es) * 2019-05-29 2021-11-17 Syngenta Crop Protection Ag Derivados de alcoxipiridina y alcoxipirimidina microbicidas
JP2023524106A (ja) * 2020-05-01 2023-06-08 コンステレーション・ファーマシューティカルズ・インコーポレイテッド Ｔｒｅｘ１のモジュレーター
KR20230144065A (ko) * 2021-02-08 2023-10-13 우한 휴먼웰 이노베이티브 드러그 리서치 앤드 디벨롭먼트 센터 리미티드 컴퍼니 피리도피리미디논계 유도체 및 이의 제조 방법과 용도
WO2024008185A1 (zh) * 2022-07-07 2024-01-11 武汉人福创新药物研发中心有限公司 包含sos1抑制剂的药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4121214A1 (de) 1991-06-27 1993-01-14 Bayer Ag 7-azaisoindolinyl-chinolon- und -naphthyridoncarbonsaeure-derivate
ID22834A (id) * 1997-04-25 1999-12-09 Pfizer Pirazolopimidinona untuk kelainan seksual
IL139456A0 (en) 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
WO2005041957A1 (en) 2003-10-29 2005-05-12 Pfizer Products Inc. Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors
AP2006003632A0 (en) 2003-12-16 2006-06-30 Pfizer Prod Inc Pyridol[2,3-D] pyrimidine-2,4-Diamines as PDE 2 inhibitors
EP1548011A1 (de) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-onderivate als PDE2 Phosphodiesterase Hemmer, deren Herstellung und therapeutische Verwendung
US7851472B2 (en) 2004-09-02 2010-12-14 Nycomed Gmbh Triazolophthalazines
ES2397080T3 (es) 2005-01-05 2013-03-04 Nycomed Gmbh Triazoloftalazinas como agentes inhibidores de la PDE2
WO2006127530A2 (en) 2005-05-25 2006-11-30 Merck & Co., Inc. Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP5161795B2 (ja) 2006-02-15 2013-03-13 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖインヒビターとしてのアミノテトラヒドロピラン
EP2069313A2 (de) 2006-06-29 2009-06-17 Alantos Pharmaceuticals Holdings, Inc. Metallproteasehemmer
KR20100045497A (ko) 2007-08-02 2010-05-03 화이자 인코포레이티드 피리미딘 및 피리딘 유도체 및 이들의 약학적 용도 및 조성물
US8129398B2 (en) * 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
JP2012516333A (ja) * 2009-01-28 2012-07-19 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｉｖインテグラーゼ阻害剤としての架橋化合物
ME01923B (me) 2009-05-28 2015-05-20 Novartis Ag Supstituisani derivati aminopropionske kiseline kao inhibitori neprilizina
US8680116B2 (en) 2009-07-22 2014-03-25 Merck Sharp & Dohme Corp. Quinolinone PDE2 inhibitors
SG192576A1 (en) 2011-02-23 2013-09-30 Pfizer IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
WO2012168817A1 (en) 2011-06-07 2012-12-13 Pfizer Inc. Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
CA2838645C (en) 2011-06-27 2020-03-10 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
WO2013034755A1 (en) 2011-09-09 2013-03-14 H. Lundbeck A/S Triazolopyrazine derivatives and their use for treating neurological and psychiatric disorders
WO2013034758A1 (en) 2011-09-09 2013-03-14 H. Lundbeck A/S Substituted triazolopyrazines and uses thereof
US9056863B2 (en) 2011-09-09 2015-06-16 H. Lundbeck A/S Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof
US8530461B2 (en) 2011-12-29 2013-09-10 Boehringer Ingelheim International Gmbh Azetidine derivatives
NZ631258A (en) 2012-04-25 2016-11-25 Takeda Pharmaceuticals Co Nitrogenated heterocyclic compound
US9527841B2 (en) 2012-07-13 2016-12-27 Takeda Pharmaceutical Company Limited Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2014139983A1 (en) 2013-03-13 2014-09-18 H. Lundbeck A/S [1,2,4]triazolo[4,3-a]quinoxalines as dual pde2/pde10 inhibitors
EP3026051A4 (de) 2013-07-24 2017-03-08 Takeda Pharmaceutical Company Limited Heterocyclische verbindung
WO2015060368A1 (ja) * 2013-10-23 2015-04-30 武田薬品工業株式会社 複素環化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
EP3294297A1 (de) 2018-03-21
US10285989B2 (en) 2019-05-14
WO2016186888A1 (en) 2016-11-24
US20180256575A1 (en) 2018-09-13
EP3294297A4 (de) 2018-12-12
WO2016183741A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
EP3319966B1 (de) Bicyclische heterocyclische verbindungen als pde2-hemmer
US8691827B2 (en) Amino tetrahydro-pyridopyrimidine PDE10 inhibitors
JP2019523233A (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
US8492392B2 (en) Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors
US10370336B2 (en) Phenyl-cyanoquinolinone PDE9 inhibitors
EP3270926B1 (de) Triazolylpyrimidinonverbindungen als pde2-inhibitoren
EP2621276B1 (de) 2-alkoxy-pyrimidin-pde10-hemmer
EP3302484B1 (de) 6-alkyl-dihydropyrazolopyrimidinon-verbindungen als pde2-inhibitoren
US8957077B2 (en) Pyrazolopyrimidine PDE 10 inhibitors
EP3302486B1 (de) Dihydropyrazolopyrimidinonverbindungen als pde2-inhibitoren
EP3294297B1 (de) Pyrimidinonamidverbindungen als pde2-inhibitoren
EP3313852B1 (de) Substituierte bicyclische pyrazolo/imidazolo-verbindungen als pde2-inhibitoren
EP3087060B1 (de) Pyrimidon-carboxamid-verbindungen als pde2-inhibitoren
EP3285581B1 (de) Pyrazolylpyrimidinonverbindungen als pde2-inhibitoren
EP3291817B1 (de) Heteroaryl-pyrimidinon-verbindungen als pde2-inhibitoren

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20181114

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/513 20060101ALI20181108BHEP

Ipc: A61K 31/505 20060101AFI20181108BHEP

Ipc: C07D 233/96 20060101ALI20181108BHEP

Ipc: C07D 239/24 20060101ALI20181108BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190712

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016026565

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1213822

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200115

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200318

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200319

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200513

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200418

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016026565

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1213822

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191218

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

26N No opposition filed

Effective date: 20200921

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200531

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200531

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200510

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200510

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191218

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602016026565

Country of ref document: DE

Owner name: MERCK SHARP & DOHME LLC, RAHWAY, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., RAHWAY, N.J., US

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20221013 AND 20221019

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230412

Year of fee payment: 8

Ref country code: DE

Payment date: 20230412

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230412

Year of fee payment: 8